

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

EYENOVIA, INC.,

Petitioner,

v.

SYDNEXIS, INC.,

Patent Owner.

Case No. IPR2022-00964

U.S. Patent No. 9,770,447

PETITION FOR INTER PARTES REVIEW

TABLE OF CONTENTS

	<u>Page</u>
I. Introduction.....	1
II. Technology Background.....	1
A. Low-Concentration Atropine Formulations for the Treatment of Myopia.....	1
B. Stability of Atropine in Aqueous Solution.....	3
C. Deuterium Solvent Isotope Effect.....	4
III. Scope and Content of the Prior Art	6
A. <i>Chia</i>	6
B. <i>Kondritzer</i>	8
C. <i>Siegel</i>	10
D. <i>Remington</i>	11
IV. The '447 Patent.....	13
A. The Specification.....	13
B. Prosecution History	15
1. Prosecution of the parent '199 patent	15
2. Prosecution of the '447 patent	16
C. Priority.....	21
V. Level of Ordinary Skill in the Art	22
VI. Claim Construction – “Extended period of time”	22
VII. Statement of Precise Relief Requested.....	23
VIII. Ground 1: Claims 1–3, 6–7, and 12–19 Would Have Been Obvious Over <i>Chia</i> and <i>Siegel</i> in view of <i>Kondritzer</i>	23
A. Summary of the Combination	23
B. Motivation and Reasonable Expectation of Success.....	25
1. A POSA Would Have Been Motivated to Formulate a Low-Concentration Atropine Solution with Long-Term Stability	25

2.	A POSA Would Have Been Motivated to Use D ₂ O to Increase Long-Term Stability of a Low-Concentration Atropine Formulation.....	27
3.	A POSA Would Have Had a Reasonable Expectation of Success in Substituting D ₂ O for H ₂ O in a Low-Concentration Atropine Formulation.....	31
C.	Claim-by-Claim Analysis.....	32
1.	Claim 1	32
2.	Claim 2.....	39
3.	Claim 3.....	40
4.	Claims 6 and 7.....	41
5.	Claim 12.....	42
6.	Claim 13.....	43
7.	Claim 14.....	44
8.	Claim 15.....	44
9.	Claim 16.....	44
10.	Claim 17.....	45
11.	Claim 18.....	46
12.	Claim 19.....	46
IX.	Ground 2: Claims 1–19 Would Have Been Obvious over <i>Chia, Siegel, Kondritzer, and Remington</i>	47
A.	Summary of the Combination	47
B.	Claim-by-Claim Analysis.....	48
1.	Claims 1–3, 6–7, and 12–19.....	48
2.	Claims 4 and 5.....	49
3.	Claims 8 and 9.....	50
4.	Claim 10.....	51
5.	Claim 11.....	52
X.	Alleged Unexpected Results.....	54
A.	A Solvent Isotope Effect Was Not Unexpected.....	54

B.	Data Presented During Prosecution.....	55
1.	Better Stability Was Not Unexpected.....	56
2.	Lower Main Degradant Was Not Unexpected.....	57
3.	Longer Shelf Life Was Not Unexpected.....	59
C.	The Alleged Unexpected Results Are Neither Significant Nor Commensurate With the Scope of the Claims	59
XI.	Non-Institution Under 35 U.S.C. § 325 Would Be Improper	61
XII.	Mandatory Notices Under 37 C.F.R. § 42.8.....	64
A.	Real Parties-in-Interest.....	64
B.	Related Matters.....	64
C.	Lead and Back-Up Counsel, and Service Information	66
XIII.	Grounds for Standing.....	66
XIV.	Payment of Fees.....	67
XV.	Conclusion	67

TABLE OF AUTHORITIES**Page(s)****Federal Cases**

<i>Accord Healthcare Inc. v. Daiichi Sankyo Co., Ltd.</i> , IPR2015-00864, Paper 104 (PTAB Sept. 12, 2016).....	60
<i>Alcon Res., Ltd. v. Apotex Inc.</i> , 687 F.3d 1362 (Fed. Cir. 2012)	37
<i>Amgen, Inc. v. F. Hoffman-La Roche Ltd.</i> , 580 F.3d 1340 (Fed. Cir. 2009)	31
<i>Atlas Powder Co. v. IRECO, Inc.</i> , 190 F.3d 1342 (Fed. Cir. 1999)	<i>passim</i>
<i>Becton, Dickinson & Co. v. B. Braun Melsungen AG</i> , IPR2017-01586, Paper 8 (PTAB Dec. 15, 2017)	61, 62
<i>Comaper Corp. v. Antec, Inc.</i> , 596 F.3d 1343 (Fed. Cir. 2010)	42, 50, 51
<i>Conopco, Inc. v. The Proctor & Gamble Company</i> , IPR2013-00505, Paper 69 (PTAB Feb. 10, 2015).....	35
<i>Daiichi Sankyo Co. v. Matrix Labs., Ltd.</i> , 619 F.3d 1346 (Fed. Cir. 2010)	29, 35
<i>E.I. DuPont de Nemours & Co. v. Synvina C.V.</i> , 904 F.3d 996 (Fed. Cir. 2018)	36, 60
<i>Eli Lilly & Co. v. Zenith Goldline</i> , 471 F.3d 1369 (Fed. Cir. 2006)	59
<i>Galderma Labs., L.P. v. Tolmar, Inc.</i> , 737 F.3d 731 (Fed. Cir. 2013)	59
<i>In re Baxter Travenol Labs.</i> , 952 F.2d 388 (Fed. Cir. 1991)	39, 54

<i>In re Grasselli</i> , 713 F.2d 731 (Fed. Cir. 1983)	60
<i>In re Peterson</i> , 315 F.3d 1325 (Fed. Cir. 2003)	37
<i>Incyte Corp. v. Concert Pharms. Inc.</i> , IPR2017-01256, Paper 119 (PTAB Apr. 8, 2019)	29, 35, 36
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	40, 46, 47
<i>Netflix Inc. v. Hulu LLC</i> , IPR2020-00558, Paper 10 (PTAB Aug. 26, 2020).....	62
<i>New Railhead Mfg. L.L.C. v. Vermeer Mfg. Co.</i> , 298 F.3d 1290 (Fed. Cir. 2002)	21
<i>Okajima v. Bourdeau</i> , 261 F.3d 1350 (Fed. Cir. 2001)	22
<i>Ormco Corp. v. Align Tech., Inc.</i> , 463 F.3d 1299 (Fed. Cir. 2006)	37
<i>Oticon Med. AB v. Cochlear Ltd.</i> , IPR2019-00975, Paper 15 (PTAB Oct. 16, 2019).....	63
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007)	35
<i>Phillips v. AWH Corp.</i> , 415 F.3d 1303 (Fed. Cir. 2005)	23
<i>Santarus, Inc. v. Par Pharms., Inc.</i> , 694 F.3d 1344 (Fed. Cir. 2012)	39
<i>Unwired Planet, LLC v. Google Inc.</i> , 841 F.3d 995 (Fed. Cir. 2016)	7, 9, 11, 13
Federal Statutes	
35 U.S.C. § 102(a)(1).....	<i>passim</i>

35 U.S.C. § 103	17, 19, 23
35 U.S.C. § 112	16, 21
35 U.S.C. § 325	61, 63

TABLE OF EXHIBITS

Exhibit	Description
1001	U.S. Patent No. 9,770,447 to Ostrow et al.
1002	Declaration of Dr. Stephen Byrn, Ph. D.
1003	Chia et al., <i>Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)</i> , OPTHALMOLOGY 119(2): 347–354 (2012)
1004	Albert A. Kondritzer & Peter Zvirblis, <i>Stability of Atropine in Aqueous Solution</i> , J. AM. PHARM. ASS'N 46(9):531–535 (1957)
1005	John D. Mullins & Gerald Hecht, <i>Pharmaceutical Necessities and Ophthalmic Preparations</i> , in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME II 1380–1416, 1563–1576 (Alfonso R. Gennaro ed., 19 th ed. 1995)
1006	Siegel et al., <i>Stability of Procaine in Deuterium Oxide</i> , J. PHARM. SCIS. 53(8):978–979 (1964)
1007	Reserved
1008	Reserved
1009	McBrien et al., <i>Point-Counterpoint. How does atropine exert its anti-myopia effects?</i> , OPTHALMIC & PHYSIOL OPT. 33:373–378 (2013)
1010	Chua et al., <i>Atropine for the Treatment of Childhood Myopia</i> , OPTHALMOLOGY 113(12):2285–2291 (2006)
1011	Shih et al., <i>An intervention trial on efficacy of atropine and multi-focal glasses in controlling myopic progression</i> , ACTA OPTHALMOLOGICA SCANDINAVICA 79:233–236 (2001)
1012	U.S. Patent Publication No. 2007/0254914 to Wu et al.
1013	Lee et al., <i>Prevention of Myopia Progression with 0.05% Atropine Solution</i> , J OCUL PHARMACOL THER. 22(1):41–46 (2006)

Exhibit	Description
1014	Fang et al., <i>Prevention of Myopia Onset with 0.025% Atropine in Premyopic Children</i> , J OCUL PHARMACOL THER. 26(4):341–345 (2010)
1015	Shih et al., <i>Effects of Different Concentrations of Atropine on Controlling Myopia in Myopic Children</i> , J OCUL PHARMACOL THER. 15(1):85–90 (1999)
1016	Wu et al., <i>The Long-Term Results of Using Low-Concentration Atropine Eye Drops for Controlling Myopia Progression in Schoolchildren</i> , J OCUL PHARMACOL THER. 27(5):461–466 (2011)
1017	Chia et al., <i>Atropine for the Treatment of Childhood Myopia: Changes after Stopping Atropine 0.01%, 0.1% and 0.5%</i> , AM. J. OPHTHALMOLOGY 157(2):451–457.e1 (2014)
1018	International Publication No. WO 2012/161655 to Donald Tan and Wei Han Chua
1019	Zvirblis et al., <i>The Kinetics of the Hydrolysis of Atropine</i> , J. AM. PHARM. ASS'N 45(7): 450–454 (1956)
1020	Schier et al., <i>Preparing for Chemical Terrorism: Stability of Injectable Atropine Sulfate</i> , ACAD. EMERG. MED. 11(4):329–334 (2004)
1021	Kushner et al., <i>Pharmacological uses and perspectives of heavy water and deuterated compounds</i> , CAN. J. PHYSIOL. PHARMACOL. 77:79–88 (1999)
1022	Blake et al., <i>Studies with Deuterated Drugs</i> , J. PHARM. SCIS. 64(3):367–391 (1975)
1023	Thomas G. Gant, <i>Using Deuterium in Drug Discovery: Leaving the Label in the Drug</i> , J. MED. CHEM. 57(9):3595–3611 (2014)
1024	Allan B. Foster, <i>Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design</i> , ADVANCES IN DRUG RESEARCH 14:1–40 (1985)
1025	Katherine B. J. Schowen, <i>Solvent Hydrogen Isotope Effects</i> , TRANSITION STATES OF BIOCHEM. PROCESSES 225–283 (Richard D. Gandour & Richard L. Schowen eds., 1978)
1026	Paul K. Glasoe & F. A. Long, <i>Use Of Glass Electrodes To Measure Acidities In Deuterium Oxide</i> , J. PHYS. CHEM. 64(1):188–190 (1960)

Exhibit	Description
1027	Sen et al., <i>Role of heavy water in biological sciences with an emphasis on thermostabilization of vaccines</i> , EXPERT REV. VACCINES 8(11): 1587–1602 (2009)
1028	U.S. Patent Publication No. 2011/0076331 to Bayerl
1029	Kho Kiat Nee, <i>The Use Of Deuterium Oxide To Stabilize Pharmaceuticals Against Chemical Degradation</i> , Slide Serve - Theophilus Stavros (2014), available at https://www.slideserve.com/theophilus-stavros/the-use-of-deuterium-oxide-to-stabilize-pharmaceuticals-against-chemical-degradation
1030	Peter Krumbiegel, <i>Large deuterium isotope effects and their use: a historical review</i> , ISOTOPES IN ENVTL. & HEALTH STUDIES 47(1):1–17 (2011)
1031	Amanda Yarnell, <i>Heavy-Hydrogen Drugs Turn Heads, Again</i> , CHEMICAL & ENG’G NEWS 87(25):36–39 (2009)
1032	Graham S. Timmins, <i>Deuterated drugs; where are we now?</i> , EXPERT OPIN. THER. PAT. 24(10):1067–1075 (2014)
1033	Anschel et al., <i>Parenteral Formulation VI: Hydrolytic Degradation of Esters in Parenteral Solutions</i> , BULLETIN OF THE PARENTERAL DRUG ASS’N 26(6):271–289 (1972)
1034	Filed Application of U.S. Patent No. 9,421,199, May 29, 2015
1035	U.S. Patent No. 9,421,199, Non-Final Rejection, March 7, 2016
1036	U.S. Patent No. 5,716,952 to WoldeMussie et al.
1037	U.S. Patent Publication No. 2012/0015035 to Wildsoet et al.
1038	U.S. Patent Publication No. 2012/0203161 to Herekar
1039	U.S. Patent No. 9,421,199, Response to Non-Final Rejection, April 5, 2016
1040	U.S. Patent No. 9,421,199, Interview Summary, April 13, 2016
1041	U.S. Patent No. 9,421,199, Notice of Allowance, June 13, 2016

Exhibit	Description
1042	U.S. Patent No. 9,770,447, Advisory Action, April 13, 2017
1043	Provisional Patent Application No. 60/016,502
1044	Provisional Patent Application No. 62/096,433
1045	Certified English Translation of CN 101049287A to Wu Peichang et al.
1046	Chowhan et al., <i>Ophthalmic Preparations</i> , in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY 907929 (22 nd ed. 2013)
1047	Lallemand et al., <i>Successfully Improving Ocular Drug Delivery Using the Cationic Nanoemulsion</i> , Novasorb, J. DRUG DELIVERY 2012:1–16 (2012)
1048	Rajpal et al., <i>Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence</i> , PATIENT PREFER ADHERENCE 8:925–31 (2014)
1049	Kirchhoff et al., <i>Analysis of atropine, its degradation products and related substances of natural origin by means of reversed-phase high-performance liquid chromatography</i> , J. CHROMATOGRAPHY A 1046:115–120 (2004)
1050	Garcia-Valdecabres et al., <i>pH Stability of ophthalmic solutions</i> , OPTOMETRY 75(3):161–168 (2004)
1051	PB Patel et al., <i>Ophthalmic Drug Delivery System: Challenges and Approaches</i> , SYSTEMATIC REVIEWS IN PHARMACY 1(2):113–120 (2010)
1052	European Patent Publication No. 0332826 to Zev Tashma
1053	PHYSIOCHEMICAL PRINCIPLES OF PHARMACY 56–92 (4 th ed. 2006)
1054	Stephen S. Minor & Richard L. Schowen, <i>One-Proton Solvation Bridge in Intramolecular Carboxylate Catalysis of Ester Hydrolysis</i> , J. AM. CHEM. SOC. 95(7):2279–2281 (1973)
1055	DRUG REPOSITIONING BRINING NEW LIFE TO SHELVED ASSETS AND EXISTING DRUGS 53–64, 291–343 (Michael J. Barratt & Donald E. Frail eds., 2012)
1056	Cath O’Driscoll, <i>Heavyweight drugs</i> , CHEM. & INDUS. 24–26 (2009)

Exhibit	Description
1057	UK Patent Application GB 2293100 to Ian George Stephen Furminger & Philip James Sizer
1058	U.S. Patent No. 7,691,099 to Berry
1059	U.S. Patent Publication No. 2012/0135084 to Bayerl
1060	June G. Winter and J. M. W. Scott, <i>Studies in Solvolysis. Part IV. Substituent and Solvent Isotope Effects in the Solvolysis of a Series of Benzyl Trifluoroacetates</i> , CAN. J. CHEM. 50:1886–90 (1972)
1061	William P. Jencks & Joan Carriuolo, <i>General Base Catalysis of Ester Hydrolysis</i> , J. AM. CHEM. SOC. 83(7):1743–50 (1961)
1062	Bender et al., <i>Deuterium Oxide Solvent Isotope Effects in the Nucleophilic Reactions of Phenyl Esters</i> , J. AM. CHEM. SOC. 84(4):595–599 (1962)
1063	June G. Winter & J. M. W. Scott, <i>Studies in solvolysis. Part I. The neutral hydrolysis of some alkyl trifluoroacetates in water and deuterium oxide</i> , CANADIAN J. CHEM. 46:2887–2894 (1968)
1064	Bradley A. Hanson et al., <i>A Mechanistic and Kinetic Study of the E-Ring Hydrolysis and Lactonization of a Novel Phosphoryloxymethyl Prodrug of Camptothecin</i> , PHARM. RESEARCH 20(7):1031–1038 (2003)
1065	English Translation of Jinshen Li, <i>Preparation and Quality Control of 0.04% Atropine Sulfate Eye Drops</i> , CHINA PHARMACY 17(2):111–113 (2006)
1066	Atropine Sulfate Ophthalmic Solution, Highlights of Prescribing Information, Revised July 2014
1067	Certified English Translation of Yuanda Wen, <i>Preparation and Clinical Curative Effects of 0.05% Atropine Sulfate Eye Drops</i> , CHINA PHARMACIST 11(2):194–196 (2008)
1068	Ronald F. Donnelly & Céline Corman, <i>Physical Compatibility and Chemical Stability of a Concentrated Solution of Atropine Sulfate (2 mg/mL) for Use as an Antidote in Nerve Agent Casualties</i> , INT’L J. PHARM. COMPOUNDING 12(6):550–552 (2008)

Exhibit	Description
1069	M. R. W. Brown & D. A. Norton, <i>The Preservation of Ophthalmic Preparations</i> , J. SOC. COSMETIC CHEMISTS 16:369–393 (1965)
1070	A. J. Kresge, <i>Solvent Isotope Effect in H₂O-D₂O Mixtures</i> , PURE APPL. CHEM. 8(3-4):243–258 (1964)
1071	Driver et al., <i>The Stability of Atropine Sulfate Solutions Stored in Plastic Syringes in the Operating Room</i> , ANESTH. ANALG. 89:1056–1058 (1999)
1072	Food Drug Administration Center for Drugs Evaluation Research GUIDANCE FOR INDUSTRY: DRUG STABILITY GUIDELINES (DECEMBER 9, 2008)
1073	DICTIONARY OF CHEMISTRY (2 nd ed. 2003)
1074	Sodium phosphate monobasic Safety Data Sheet, Version 1.1, G-BIOSCIS. (Jan. 9, 2012)
1075	Sodium Phosphate Dibasic, Anhydrous Material Safety Data Sheet, SCHOLAR CHEM. (Jan. 23, 2009)
1076	Pfannkoch, <i>The Preparation of Buffers and Other Solutions: A Chemist's Perspective</i> , MOLECULAR BIOLOGY PROBLEM SOLVER: A LABORATORY GUIDE Ch. 3:31–47 (Alan S. Gerstein ed., 2001)
1077	HANDBOOK OF PHARMACEUTICAL EXCIPIENTS 5–7, 193–196, 281–284, 351–352, 741–742, 984–989 (Raymond C. Rowe et al. eds., 7 th ed. 2012)
1078	International Patent Publication No. WO 2013/167865 to Purandare
1079	U.S. Patent Publication No. 2008/0300316 to Gant et al.
1080	Waterman et al., <i>Hydrolysis in Pharmaceutical Formulations</i> , PHARM. DEV. & TECH. 7(2):113–146 (2002)
1081	Lin et al., <i>Formulation and stability of an extemporaneous 0.02% chlorhexidine digluconate ophthalmic solution</i> , J. FORMOSAN MED. ASS'N 114:1162–1169 (2015)
1082	Susina et al., <i>Effect of Deuterium Oxide on Local Anesthetic Activity of Procaine</i> , J. PHARM. SCIS. 51(12):1166–1169 (1962)
1083	Dimitrios Stefanidis & William P. Jencks, <i>General Base Catalysis of Ester Hydrolysis</i> , J. AM. CHEM. SOC. 115:6045–6050 (1993)

Exhibit	Description
1084	Berton et al., <i>Stability of Ophthalmic Atropine Solutions for Child Myopia Control</i> , PHARMACEUTICS 12(8):781 (2020)
1085	John D. Mullins & Gerald Hecht, <i>Tonicity, Osmoticity, Osmolality and Osmolarity and Stability of Pharmaceutical Products</i> , in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, VOLUME I 613–627, 639–647 (Alfonso R. Gennaro ed., 19 th ed. 1995)
1086	Atropine Sulfate Ophthalmic Solution, Highlights of Prescribing Information, Revised July 2014, Wayback Machine and Affidavit
1087	Badaró et al., <i>Retinal Biocompatibility of Brilliant Blue G with Deuterated Water for Chromovitrectomy</i> , J. OPHTHALMIC & VISION RESEARCH 9(2):204–209 (2014)
1088	International Publication No. WO 94/21298 to Karl Simpson & Radu Crainic
1089	U.S. Application No. 16/805,612, Information Disclosure Statement, March 2, 2020
1090	U.S. Patent No. 9,770,447, Preliminary Amendment and Response to Notice to File Missing Parts, August 3, 2013
1091	U.S. Patent No. 9,770,447, Non-Final Office Action, September 30, 2016
1092	U.S. Patent No. 9,770,447, Information Disclosure Statement and International Search Report, November 17, 2016
1093	U.S. Patent No. 9,770,447, Final Rejection, January 25, 2017
1094	U.S. Patent No. 9,770,447, Response to Final Office Action, March 21, 2017
1095	U.S. Patent No. 9,770,447, AFCEP2.0 Response to Final Office Action Dated and Advisory Action, April 21, 2017
1096	Peter Zvirblis & Robert I. Ellin, <i>Kinetics and Stability of a Multicomponent Organophosphate Antidote Formulation in Glass and Plastic</i> , J. PHARM. SCI. 71(3):321–325 (1982)
1097	U.S. Patent No. 9,770,447, Notice of Allowance, May 30, 2017
1098	U.S. Patent No. 9,770,447, Certificate of Correction

I. Introduction

Petitioner Eyenovia, Inc. respectfully requests *inter partes* review of U.S. Patent No. 9,770,447 (the “447 patent”) (EX1001), assigned to Patent Owner Sydnexis Inc., and cancellation of claims 1–19.

The challenged claims recite nothing more than conventional low-concentration atropine formulations with deuterium oxide (D₂O) in place of regular water (H₂O) to increase the formulation’s stability at pH levels known to be optimal for clinical administration. As of the effective filing date, the use of D₂O to improve stability was well known and was specifically expected to be “of value, for example, in the extemporaneous preparation of ophthalmic solutions, where stability and sterility are important considerations.” EX1006, 4. As the Examiner explained during prosecution of the ’447 patent, “increased stability *is the expected property*” of combining D₂O and atropine. EX1042, 3. There was nothing inventive about substituting D₂O for H₂O to achieve the very result—*i.e.*, increased stability—that would have been expected.

II. Technology Background

A. Low-Concentration Atropine Formulations for the Treatment of Myopia

Atropine, a nonselective muscarinic antagonist, has been studied extensively for more than a century and has been described as “the oldest and most effective pharmacological treatment to inhibit the development of myopia.” EX1009, 1;

EX1003, 13. Early clinical trials established that 1.0% and 0.5% atropine formulations were effective in reducing the progression of myopia. EX1010, 1; EX1011, 1; EX1003, 13; EX1012 ¶[0006]. At these high concentrations, however, atropine was known to cause side effects, such as photophobia, cycloplegia, and mydriasis, which lead to poor patient compliance. EX1003, 13; EX1012 ¶[0006]; EX1013, 2; EX1014, 3; EX1015, 1. Because treating myopia with atropine requires long-term use, this poor patient compliance resulted in reduced efficacy, especially in adolescent populations. EX1002 ¶¶22–24; EX1016, 3–4.

In an effort to reduce the side effects, researchers studied $\leq 0.03\%$ atropine solutions and reported that clinical efficacy could be maintained with an improved safety profile. EX1003, 13, 15–20; EX1014, 1; EX1017, 1. For instance, Fang reported that 0.025% atropine eye drops prevented myopia onset and myopic shift (EX1014, 1, 3), and Chia observed that 0.01% atropine “had significant clinical effects as evident by its effect on myopia progression, accommodation, and pupil size,” and that “atropine-related adverse effects were uncommon at the 0.01% dose.” EX1003, 19. A patent application directed to the work of Chia, WO 2012/161655, claimed ophthalmic formulations containing 0.001% to 0.0249% atropine and methods of treating myopia progression. EX1018, 19:12–13, 4:20–5:2; claims 1–5, 12–18.

Thus, as of at least 2014, it was well established that $\leq 0.03\%$ atropine solutions were clinically effective in treating and/or preventing myopia and had an improved safety profile compared to high-concentration atropine formulations. EX1003, 13, 15–20; EX1014, 1; EX1017, 1; EX1002 ¶¶25–36.

B. Stability of Atropine in Aqueous Solution

The stability of atropine is primarily dependent on temperature and pH.¹ *E.g.*, EX1004, 5; EX1019, 1. This was known as early as the 1950s, when *Kondritzer* and *Zvirblis* conducted a series of studies demonstrating that the half-life of atropine in solution could be predicted for any temperature and pH. *E.g.*, EX1004, 8; EX1019, 5.

As shown in Figure 1, atropine is a carboxylic ester; in aqueous solution it degrades via classic ester hydrolysis. EX1019, 1; EX1004, 6; EX1020, 5; EX1002 ¶37.




Figure 1. Atropine hydrolysis reaction. Red denotes ester.

¹ pH is a measure of H^+ concentration. Low pH values represent high H^+ concentrations (and low OH^- concentrations). EX1002 ¶40.

Ester hydrolysis reactions are catalyzed by both H^+ ions (“acid-catalyzed hydrolysis”) and OH^- ions (“base-catalyzed hydrolysis”). EX1004, 6; EX1002 ¶¶38–39. The rate of degradation (k) is equal to the sum of the acid-catalyzed and base-catalyzed reactions. EX1004, 6. For atropine, the rate of the acid-catalyzed reaction is much slower than that of the base-catalyzed reaction, such that the stability of atropine “is governed by the hydroxyl-ion $[OH^-]$ concentration....” *Id.*, 5, 8. At low OH^- concentrations (*i.e.*, $pH < \sim 3-5$) the overall rate of reaction is slow, and atropine is relatively stable. *Id.*, 8–9. As OH^- concentration increases, however, the overall rate of the reaction increases, and atropine becomes more unstable ($pH > \sim 5$). *Id.*

C. Deuterium Solvent Isotope Effect

Deuterium is a stable isotope of hydrogen that has twice the mass of the regular hydrogen (also known as protium). EX1021, 2. Because of the larger nucleus in deuterium, replacing hydrogen with deuterium results in an increase in bond strength, which often slows the rate of reaction. EX1002 ¶41; EX1022, 3; EX1023, 5–9. The difference in the rate of a reaction between the deuterated compound and its hydrogen analog is known as the “kinetic isotope effect” or KIE. EX1024, 4–5.

Replacing hydrogen with deuterium in regular water (H_2O) results in deuterium oxide (D_2O).² EX1025, 19. Similar to the KIE, the degradation of compounds in D_2O will often proceed more slowly than in H_2O . EX1002 ¶42; EX1025, 20–25; EX1027, 3; EX1028 ¶[0012]. The difference in the rate of reaction in D_2O compared to that in H_2O is the sum of medium, primary, and secondary effects and is known as the kinetic solvent isotope effect (“KSIE” or “SIE”). EX1002 ¶¶42–47; EX1025, 19.

Aside from these differences, deuterium is remarkably similar to hydrogen in most other respects. EX1025, 21 (“Certainly it is true that isotopic substitution is the least disturbing structural change that can be made in a system....”); EX1028 ¶[0011]; EX1023, 8–9; EX1002 ¶¶55–56. For nearly a century, this targeted effect—slowing reactions while leaving other properties unchanged—had been extensively studied and had generated a voluminous body of literature. *E.g.*, EX1025, 22–23; EX1027, 3. By 2014, it was well understood that the effect of D_2O

² The pH of a solution of deuterium oxide is referred to as “pD.” The difference between pH and pD can be calculated by the standard equation $\text{pD} = \text{metered reading} + 0.4$. EX1025, 37; EX1026, 1; EX1001, 33:21–27. For example, a measurement of pH 4 in pure D_2O is equivalent to pD 4.4. *Id.*; EX1002 ¶42, n.5.

on a given compound could be predicted by its effect on analogous compounds and reactions. EX1002 ¶¶48–54; EX1025, 26, 32, 45.

In the years preceding the effective filing date of the '447 patent, there was great interest in using deuterium to improve upon existing pharmaceutical formulations. *See, e.g.*, EX1029, 1³; EX1030, 13–14; EX1031, 3–5; EX1032, 14–16; EX1002 ¶¶64–65. Given its predicable KIE and KSIE effects, deuterium offered a simple and relatively inexpensive way to improve the stability of known therapeutics without reducing their clinical efficacy. EX1029, 20; EX1023, 8–9, 16–17; EX1002 ¶¶57–63. Indeed, by 2014, several companies were dedicated exclusively to using deuterium to improve known therapeutics. *E.g.*, EX1031, 3–5.

III. Scope and Content of the Prior Art

A. *Chia*

“Atropine for the Treatment of Childhood Myopia: Safety and Efficacy of 0.5%, 0.1%, and 0.01% Doses (Atropine for the Treatment of Myopia 2)” by Chia et al. (EX1003, “*Chia*”) published in 2012, and constitutes prior art under at least 35 U.S.C. § 102(a)(1). *Chia*’s prior art public accessibility is evidenced at least by (1) its date of online publication, October 2, 2011 (EX1003, 20); (2) date stamp

³ Patent Owner disclosed EX1029 with a date of 1/11/2014 in another application. EX1089, 13.

reporting it was received February 2012 (EX1003, 2); (3) publication in a well-known and reputable journal, *Ophthalmology*; and (4) the fact that it was cited by skilled artisans prior to June 24, 2014 (*e.g.*, EX1017, 7). EX1002 ¶18, n.1. *Chia* discloses the use of solutions comprising 0.001%–0.03% atropine via eye drops to arrest myopia. *E.g.*, EX1003, 13, 19–20.

As *Chia* recognized, prior treatments with “atropine 1% eyedrops were effective in controlling myopic progression” but caused harmful side effects, such as cycloplegia and mydriasis. EX1003, 13. To address this, *Chia* tested lower concentration formulations and reported that “atropine 0.01% has minimal side effects compared with atropine at 0.1% and 0.5%, and retains comparable efficacy in controlling myopia progression.” EX1003, 13. Based on these results, *Chia* concluded that “[t]he lowest concentration of 0.01% atropine...is a viable concentration for reducing myopia progression” and that “the 0.01% formulation exhibited fewer adverse events” than 1%, 0.1%, and 0.5% atropine. EX1003, 19–20.

Chia is analogous art to the ’447 patent. It “is from the same field of endeavor”—ophthalmic compositions—and is reasonably pertinent to “one of the particular problems dealt with by the inventor”—reducing atropine side effects in the treatment of myopia. *Unwired Planet, LLC v. Google Inc.*, 841 F.3d 995, 1000–01 (Fed. Cir. 2016) (citation omitted); EX1002 ¶18, n.1. *Chia* was neither cited nor considered during prosecution of the ’447 patent.

B. *Kondritzer*

“*Stability of Atropine in Aqueous Solution*” by Kondritzer and Zvirblis (EX1004, “*Kondritzer*”) published in 1957, and constitutes prior art under at least 35 U.S.C. § 102(a)(1). *Kondritzer*’s prior art public accessibility is evidenced at least by (1) its date of publication, September 1957 (EX1004, 1–4); (2) publication in a well-known and reputable journal, *Journal of the American Pharmaceutical Association* (EX1004, 1); and (3) the fact that it was cited by skilled artisans prior to June 24, 2014 (EX1020, 7; EX1052, 8; EX1033, 19). EX1002 ¶18, n.3. *Kondritzer* “evaluate[d] the factors involved in the deterioration of aqueous solutions of atropine and its salts.” EX1004, 5. *Kondritzer* reviewed several studies examining the rate of degradation of atropine at different temperatures and pH levels. EX1004, 5–6.

Kondritzer explained that “[h]ydrolytic reactions catalyzed by both hydrogen and hydroxyl ions, with no detectable *water* reaction, include hydrolysis of carboxylic esters.” *Id.*, 6. *Kondritzer* confirmed that degradation of atropine is primarily due to acid- and base-catalyzed hydrolysis and noted a prior study reporting that this is also “true for the hydrolysis of procaine.”⁴ *Id.* *Kondritzer*

⁴ Procaine is used as a topical anesthetic in ophthalmic formulations. EX1006, 4. Like atropine, it is a carboxylic ester. EX1033, 1.

further disclosed that the effects of both the acid- and base-catalyzed reactions are “governed by the hydroxyl-ion concentration and the temperature.” *Id.*, 5.

Kondritzer derived an equation to predict the pH at which atropine would be most stable for any hydrogen ion concentration. *Id.*, 6. To test the validity of their equation, *Kondritzer* measured the rate of hydrolysis (k) of atropine at different pHs. *Id.*, 6–8. *Kondritzer* found that the half-lives of atropine at various temperatures and pHs determined experimentally matched those predicted by their theoretical equation. *Id.*, 8.

Based on this data and a prior study of atropine hydrolysis at higher pHs, *Kondritzer* concluded that, “[a]s expected, the hydrogen ion catalyzed hydrolysis of atropine is slow” and that, “[a]bove pH 4.5, the predominant catalytic reaction involves hydroxyl ion; below pH 3, the predominant catalytic reaction involves hydrogen ion....” *Id.*, 8–9.

Kondritzer is analogous art to the ’447 patent. It “is from the same field of endeavor”—atropine solutions—and reasonably pertinent to “one of the particular problems dealt with by the inventor”—optimizing pH levels for clinical administration and long-term stability. *Unwired Planet*, 841 F.3d at 1000–01 (citation omitted); EX1002 ¶18, n.3. *Kondritzer* was neither cited nor considered during prosecution of the ’447 patent.

C. Siegel

“Stability of Procaine in Deuterium Oxide” by Siegel et al. (EX1006, “*Siegel*”) published in 1964, and constitutes prior art under at least 35 U.S.C. § 102(a)(1). *Siegel*’s prior art public accessibility is evidenced at least by (1) its date stamp, August 18, 1964 (EX1006, 1); (2) publication in a well-known and reputable journal, *Journal of Pharmaceutical Sciences* (EX1006, 1–3); and (3) the fact that it was cited by skilled artisans prior to June 24, 2014 (*e.g.*, EX1052, 2). EX1002 ¶18, n.2. *Siegel* discloses the use of D₂O to increase the stability of aqueous ophthalmic solutions. EX1006, 4.

Siegel recognized the potential benefit of substituting D₂O for regular water in ophthalmic solutions, explaining that D₂O resembles ordinary water “more closely than any other solvent” and could be used in ophthalmic solutions. *Id.* *Siegel* explicitly states that deuterium oxide “may prove of value, for example, in the extemporaneous preparation of ophthalmic solutions, where stability and sterility are important considerations.” *Id.* *Siegel* further noted that an earlier study found that the efficacy of procaine in D₂O increased “by a factor of 2” and explained that the increased efficacy is “attributed to a greater stability (in vivo) of procaine base in deuterium oxide.” *Id.*, 5.

Against this backdrop, *Siegel* studied the effect of D₂O on procaine, an ophthalmic compound used as a local anesthetic. *Id.*, 4. Based on an earlier study

showing that the hydrolysis of procaine “was shown to increase with hydroxide ion concentration,” *Siegel* theorized that substituting deuterium oxide—which has a lower hydroxide ion concentration than water at equivalent pHs—would reduce the rate of hydrolysis and produce a more stable solution. *Id.*

Siegel’s study showed that “the rate of deuteriolysis of procaine is less than the rate of hydrolysis.” *Id.*, 5. *Siegel* concluded that “increased stability in D₂O is not simply a pH effect.” *Id.*

Siegel is analogous art to the ’447 patent. It “is from the same field of endeavor”—ophthalmic solutions—and reasonably pertinent to “one of the particular problems dealt with by the inventor”—improving the clinical efficacy and long-term stability of ophthalmic solutions. *Unwired Planet*, 841 F.3d at 1000–01 (citation omitted); EX1002 ¶18, n.2. Although the Applicant identified *Siegel* in an Information Disclosure Statement during prosecution, the Examiner never discussed or analyzed *Siegel* in any office action.

D. Remington

“Ophthalmic Preparations” and “Pharmaceutical Necessities” in the nineteenth edition of Remington’s Pharmaceutical Sciences (EX1005, “*Remington*”) published in 1995, and constitutes prior art under at least 35 U.S.C. § 102(a)(1). Remington’s prior art public accessibility is evidenced at least by (1) its date of publication, 1995 (EX1005, 4–5); its library stamp (EX1005, 8); and (3) the fact that

it was cited by skilled artisans prior to June 24, 2014 (EX1072, 6, 24). EX1002 ¶18, n.4. *Remington* discloses conventional components of ophthalmic solutions, including a standard solution appropriate for atropine. EX1005, 52.

Regarding components, *Remington* taught “vehicles suitable for salts of Atropine” contain 0.9% sodium chloride (an osmolarity adjusting agent); benzalkonium chloride (a preservative); a buffering agent such as boric acid or a phosphate buffer (sodium acid phosphate anhydrous (a phosphate buffer); and disodium phosphate anhydrous (Na_2HPO_4), and water. *Id.*, 52. *Remington* disclosed a number of other well-known “pharmaceutical necessities” including acetic acid (*id.*, 35–36) and hydrochloric acid (*id.*, 39).

In terms of administration, *Remington* disclosed that ophthalmic solutions are “by far the most common means of administering a drug to the eye” and that “instillation of eyedrops remains...one of the more accepted means of topical drug delivery.” *Id.*, 49.

Remington further taught that balancing pH to optimize stability and administration is a key consideration when formulating ophthalmic solutions. *Id.*, 52–54. In this regard, *Remington* disclosed that “optimum patient comfort usually is found at the pH of the tear fluid, or about 7.4.” *Id.*, 52. But because most ophthalmic solutions, including atropine, are weak bases, they become unstable at higher pHs. *Id.*, 54. Accordingly, *Remington* explained that “the attainment of

optimum stability most often imposes a series of compromises on the formulator” and that “2- to 3-year stability often is achieved only by virtue of compromise.” *Id.*

Remington is analogous art to the ’447 patent. It “is from the same field of endeavor”—ophthalmic solutions—and reasonably pertinent to “one of the particular problems dealt with by the inventor”—optimizing ophthalmic solutions for clinical administration and long-term stability. *Unwired Planet*, 841 F.3d at 1000–01 (citation omitted); EX1002 ¶18, n.4. Although the specification of the ’447 patent mentioned *Remington*, it was never cited during prosecution of the ’447 patent, and there is no evidence that the Examiner considered it.

IV. The ’447 Patent

A. The Specification

The ’447 patent discloses ophthalmic atropine solutions to treat myopia. EX1001, abstract, 1:27–32, 4:26–28. As disclosed by *Chia*, the ’447 patent explains that “atropine or its pharmaceutically acceptable salts[] prevents or arrests the development of myopia in humans, for example as evidenced by reduction of the rate of increase of myopia in young people.” EX1001, 6:45–49; EX1002 ¶¶77–81.

As was also known in the art, the ’447 patent discloses that atropine solutions can be “formulated at a relatively lower pH range (*e.g.*, less than 4.5) for stability of muscarinic antagonist (*e.g.*, atropine or its pharmaceutically acceptable salts)” but that “the lower pH range in some instances causes discomfort or other side effects

such as pain or burning sensation in the eye” and “elicits a tear response which reduces the absorption of the drug in the eye and therefore the effectiveness.” EX1001, 6:61–7:5. As was known, the ’447 patent further explains that these shortcomings can be “prevented or alleviated by formulating muscarinic antagonist (*e.g.*, atropine) compositions at higher pH ranges.” EX1001, 6:65–7:2.

As *Kondritzer* recognized and disclosed, the ’447 patent notes that atropine is subject to base-catalyzed hydrolysis. EX1001, 7:23–34. As taught by *Siegel* and well understood in the art, the ’447 patent discloses that “in some instances compositions comprising deuterated water leads to reduced base catalyzed hydrolysis when compared to compositions comprising H₂O.” EX1001, 7:29–32. Thus, the use of D₂O can result in “less tear reflex in the eye.” EX1001, 7:34.

Aside from replacing H₂O with D₂O, the ’447 patent discloses nothing more than standard components well known in the art and specifically disclosed by *Remington*. For instance, the ’447 patent discloses the use of sodium chloride as an osmolarity (*id.*, 3:1–3) and tonicity (*id.*, 3:18–21) adjusting agent; a list of standard buffers used in ophthalmic solutions including phosphate, acetate, and citrate buffering agents (*id.*, 3:10–17); and pH/pD adjusting agents including acetate, bicarbonate, ammonium chloride, citrate, phosphate (*id.*, 19:11–30). Likewise, the ’447 patent discloses standard storage temperatures for atropine solutions (*id.* 59:10–

29) and a range of pD levels corresponding to pH levels known to optimize stability (pH 3–5) up to the optimum clinical efficacy (pH 7.4.) (*id.*, 12:47–13:27).

B. Prosecution History

The '447 patent is a continuation of U.S. Patent No. 9,421,199 (“the '199 patent”). With the exception of the language “comprising one and no more than one ophthalmic agent,” the claims of the '447 patent are identical to those in the '199 patent; the '447 patent is terminally disclaimed over the '199 patent.

1. Prosecution of the parent '199 patent

The original claims of the application that led to the '199 patent recited “an ophthalmic composition comprising from about 0.001 wt % to about 0.05 wt % of a muscarinic antagonist and deuterated water.” EX1034, 114. These claims were rejected as obvious over U.S. Patent No. 5,716,952 (“WoldeMussie,” EX1036), which broadly disclosed numerous muscarinic antagonists in ophthalmic formulations; U.S. Pub. No. 2012/0015035 (“Wildsoet,” EX1037), which disclosed standard components of ophthalmic compositions, *e.g.*, pH adjusting and buffering agents; and U.S. Pub. No. 2012/0203161 (“Herekar,” EX1038), which disclosed deuterated water in combination with riboflavin. EX1035, 6–8. None of these references disclosed or otherwise discussed the SIE. EX1035, 6–8.

In response, Applicant presented data disclosed in the '199 patent, allegedly showing the advantages of the formulations with D₂O over those containing H₂O.

EX1039, 9–13. Following Applicant’s response, an examiner interview “discussed the advantages of the claimed composition and referred to the portions of the specification to show such advantage.” EX1040, 2. The interview summary also mentions discussion of § 112 issues, but there is no record of any further consideration of WoldeMussie, Wildsoet, Herekar, or any other prior art references. EX1040, 2. The Examiner subsequently issued a Notice of Allowance without any further rejections. EX1041, 5–8. The reasons given for allowance were (1) an examiner’s amendment addressing various § 112 issues and (2) “the data presented to the advantages of the combination of atropine and deuterated water in comparison to the combination of atropine and water.”⁵ EX1041, 6–7.

2. Prosecution of the ’447 patent

The original claims of the ’447 patent recited “An ophthalmic composition, consisting essentially of from about 0.001 wt% to about 0.03 wt% of a muscarinic antagonist and deuterated water, at a pD of from about 4.2 to about 7.9, wherein the muscarinic antagonist is atropine, or atropine sulfate.” EX1090, 3. In the first office action, the Examiner issued a single obviousness-type double patenting rejection over the ’199 patent. EX1091, 3–4.

⁵ The claims were also amended from a “0.05%” concentration at the top end of the claimed range to “0.03%.” EX1041, 6.

Following the submission of an International Search Report (EX1092), the Examiner issued a § 103 rejection over EP 0332826 (EX1052; “*Teva*”) which taught the use of D₂O, in combination with the same two references discussed during prosecution of the ’199 patent, WoldeMussie and Wildsoet. EX1093, 4; EX1002 ¶¶298–299. More specifically, *Teva* disclosed substituting D₂O for H₂O in injectable solutions of benactyzine to increase stability and long-term shelf-life. EX1093, 4. *Teva*’s Example II specifically disclosed benactyzine in combination with atropine in D₂O. EX1052, 5. Such solutions are used for treatment of nerve agents, not myopia, and as disclosed by *Teva*, are administered at low pHs. EX1052, 5.

In response, Applicant argued that *Teva* taught stabilization of α -hydroxy carboxylic esters (e.g., benactyzine), whereas atropine is a β -hydroxy carboxylic ester. EX1094, 6. Applicant did not discuss the solvent isotope effect. *Id.*, 5–13. Nor did Applicant make the Examiner aware of the numerous carboxylic ester derivatives that had been stabilized with D₂O that did not have an α -hydroxy group, *See, e.g.*, EX1006; *see also* EX1002 ¶300–301.

Applicant further asserted that *Teva* taught atropine was stable in ordinary water, and thus, would not have been combined with the atropine references in the § 103 rejection. EX1094, 7. Applicant omitted, however, that atropine is only stable at the low pHs at which it is formulated as an injectable for the treatment of exposure

to nerve gas, as it was in *Teva*. EX1052, 4 (“[T]he pH of the composition of the invention is preferably within the range of about 2.0 to about 4.0, more preferably within the range of about 2.7. to about 2.8.”). §II.B.⁶ As a POSA would have been well aware, when used to treat myopia, atropine must be formulated at higher pHs, at which it becomes unstable. §§III.B, VIII.B; EX1002 ¶¶67–70, 302–304. Despite appearing in the file history of the ’199 patent, *Kondritzer*—which shows the relationship between pH and stability for atropine—was never disclosed during prosecution of the ’447 patent.

Applicant also submitted the same allegedly unexpected results that led to allowance of the ’199 Patent. EX1094, 9–12. As noted above, these results showed that atropine was more stable in D₂O than in H₂O. §IV.B.1.

⁶ Applicant relied on *Teva*’s Example I, which disclosed benactyzine “together with *relatively more stable* active ingredients (such as atropine and trimedoxime).” EX1094, 7. This does not teach that atropine is stable, but rather that it is *relatively more stable* than benactyzine. EX1002 ¶¶302–306. This was relevant to *Teva*, because benactyzine was the limiting reagent in these injectable formulations that included atropine and benactyzine; *i.e.*, the shelf life of the combination formulations was dependent on benactyzine, which expired before atropine. EX1096, 5; EX1002 ¶305.

Finally, to avoid *Teva*'s Example II, which specifically disclosed atropine in D₂O, Applicant argued that the claims were amended to recite “consisting essentially of” and that “*Teva*'s Example II directed to a combination formulation of benactyzine and atropine is excluded from the amended claims.” EX1094, 8.

The Examiner issued an advisory action maintaining the § 103 rejection over *Teva*, WoldeMussie and Wildsoet. EX1042, 2. The Examiner stated:

Applicant in his remarks also argues that *Teva* does not teach that the addition of D₂O would increase the stability of atropine. It is the examiner's position that the claims of the instant application are composition claims. The increased stability *is the expected property of such components being used together*.

EX1042, 3; *see also* EX1090, 3; EX1091, 3–4; EX1092, 11.⁷

The Examiner thus rejected Applicant's allegedly unexpected results, explaining that “the arguments regarding the unexpected results have been noted,” but “[i]t is the examiner's position that *such results are obtained by combination of atropine and D₂O, which is the expected property of *Teva*'s composition as well.*” *Id.* With respect to the amendment to avoid *Teva*'s Example II, the Examiner noted that “Applicant *alleges criticality to the phrase ‘consisting essentially’*” but “such

⁷ All emphasis added unless otherwise noted.

phrase is the same as ‘comprising’ in the absence of showing that the addition of other ingredients would materially effect [sic] the nature of the claimed invention.”

Id.

In a response after final, Applicant presented (1) the same arguments that benactyzine and atropine have different structures; (2) the same argument that *Teva* taught atropine was stable; and (3) the same allegedly unexpected results showing atropine was more stable in D₂O than H₂O. Compare EX1095, 5–14 with EX1094, 5–12. Additionally, Applicant amended the claims to recite “comprising one and no more than one ophthalmic agent.” EX1095, 2. In the remarks, Applicant emphasized that “*Teva Cannot Be Properly Combined with WoldeMussie and Wildsoet to Teach D₂O -Based Atropine Formulations Containing Atropine and/or Atropine Sulfate as Sole Ophthalmic Agents*” (EX1095, 7), and that “*Teva’s Example II directed to a combination formulation of benactyzine and atropine is specifically excluded from the amended claims*” (*Id.*, 10).

Following the amendments, the Examiner issued a notice of allowance. EX1097. In the reasons for allowance, the Examiner stated that: “Applicant’s amendments of April 21, 2017, amending the claims to atropine as the only active ingredient and the arguments that in the examples of EP 0332826 [*Teva*] atropine is not dissolved in deuterated water, but it is dissolved in ordinary water placed the application in condition for allowance.” EX1097, 6. Thus, the ’447 patent would

not have issued but for the amendment adding the limitation “one and no more than one ophthalmic agent.” As detailed below, this limitation has no bearing on the obviousness of the claims of the ’447 patent.

C. Priority

The ’447 patent identifies as “Related U.S. Application Data” U.S. Provisional Application Nos. 62/016,502 (“the ’502”) and 62/096,433 (“the ’433”). EX1001, cover. Neither application, however, discloses “deuterated water,” much less deuterated water in a 0.001%–0.03% atropine formulation at a pD of 4.2–7.9. Compare EX1043, p. 15–61 and EX1044, p. 15–93 with EX1001, claims 1, 14, 17. Accordingly, neither application “contain[s] a written description of the [later-claimed] invention, and of the manner and process of making and using it” as required by 35 U.S.C. § 112. EX1002 ¶¶82–83.

The challenged claims of the ’447 patent are therefore not entitled to the filing date of either the ’502 or ’433 provisional application. *See New Railhead Mfg. L.L.C. v. Vermeer Mfg. Co.*, 298 F.3d 1290, 1293 (Fed. Cir. 2002). Instead, the earliest filing date to which the challenged claims might be entitled is April 23, 2015⁸, the date of the earliest priority application to disclose D₂O.

⁸ Even if the Board should disagree, all of the prior art presented herein published more than a year before the earliest possible priority date of June 24, 2014.

V. Level of Ordinary Skill in the Art

The level of ordinary skill in the art may be reflected by the prior art of record. See *Okajima v. Bourdeau*, 261 F.3d 1350, 1355 (Fed. Cir. 2001). A person of ordinary skill in the art (“POSA”) at the time of the purported invention would have had a Ph.D. in Chemistry, Organic Chemistry, Physical Chemistry, or Pharmaceutics, with several years of experience involving preparation and/or testing of pharmaceutical formulations. A POSA would have been familiar with the common inactive ingredients used in aqueous pharmaceutical formulations and the basic characteristics of aqueous formulations such as stability, and would have had knowledge about drug degradation kinetics. EX1002 ¶¶84–85.

VI. Claim Construction – “Extended period of time”

Claims 2 and 15 recite an “extended period of time.” As used in the ’447 patent, a POSA would understand an “extended period of time” to mean “*at least about 1 week.*” Regardless of how the term is construed, however, all the challenged claims would have been obvious for the reasons set forth herein. EX1002 ¶¶86–88.

The ’447 patent specification repeatedly states that “In some embodiments, the extended period of time is one of about 1 week.” EX1001, 1:60–65, 5:19–24, 11:37–38, 24:17–23. It also defines the lower bound of other temporal embodiments as “at least one week.” For example, the specification states, “In some embodiments, the composition stored in a plastic container has a potency of at least 80% for a

period of at least 1 week....” EX1001, 24:46–52. *Phillips v. AWH Corp.*, 415 F.3d 1303, 1315 (Fed. Cir. 2005) (“[C]laims ‘must be read in view of the specification, of which they are a part.’ As we stated in *Vitronics*, the specification ‘is always highly relevant to the claim construction analysis. Usually, it is dispositive; it is the single best guide to the meaning of a disputed term.’”) (citation omitted).

VII. Statement of Precise Relief Requested

Ground	References	Basis	Claims
1	<i>Chia, Siegel, and Kondritzer</i>	§ 103	1–3, 6–7, 12–19
2	<i>Chia, Siegel, Kondritzer, and Remington</i>	§ 103	1–19

VIII. Ground 1: Claims 1–3, 6–7, and 12–19 Would Have Been Obvious Over *Chia* and *Siegel* in view of *Kondritzer*

A. Summary of the Combination

The challenged claims recite three elements: (1) *Chia*’s conventional low-concentration atropine formulation with (2) D₂O substituted for H₂O to increase the formulation’s stability at (3) pD levels that were well known to be desirable for treating myopia with atropine. EX1002 ¶¶18–21. Before the earliest possible effective filing date, it was known (*e.g.*, from *Siegel*) that D₂O could be used to increase the stability of ophthalmic compounds by reducing the rate of base-catalyzed ester hydrolysis—long understood (*e.g.*, from *Kondritzer*) to be the primary mechanism of atropine degradation. *Siegel* specifically taught that D₂O “may prove of value, for example, in the extemporaneous preparation of ophthalmic

solutions, where stability and sterility are important considerations.” EX1006, 4. By substituting D₂O for H₂O, *Siegel* observed a solvent isotope effect on procaine—an ophthalmic compound subject to base-catalyzed ester hydrolysis. *Id.*, 5.

There was ample motivation to make this substitution. EX1002 ¶¶89–92. In 2012, *Chia* disclosed that low-concentration atropine eye drops effectively treated myopia and reduced the patient compliance issues associated with higher concentration formulations. EX1003, 13, 19–20. This clinical success provided a motivation to make and use low-concentration atropine formulations that could be administered at clinically optimal pH levels—*i.e.*, those approaching the natural pH of tears (7.4) so as not to exacerbate the compliance problem *Chia* sought to remedy. EX1003, 13. Of course, ensuring stability is always a consideration in ophthalmic formulations, and it was known that stability of atropine decreases as pH increases above 5. EX1004, 6, 8; EX1005, 52. In this regard, *Siegel* and *Kondritzer* would have motivated a POSA to substitute H₂O with D₂O to increase atropine’s stability at higher pHs, and a POSA would have expected success in doing so given the solvent isotope effect and increased stability that *Siegel* reported for procaine. EX1006, 4. As a POSA would readily understand, atropine shares many similarities with procaine and would have reasonably expected the benefits in stability and clinical efficacy obtained with D₂O -procaine would translate to D₂O -atropine formulations. EX1004, 6; EX1006, 4–5.

B. Motivation and Reasonable Expectation of Success**1. A POSA Would Have Been Motivated to Formulate a Low-Concentration Atropine Solution with Long-Term Stability**

Atropine eye drops had long been used to treat myopia at concentrations of 0.5% and 1%. *E.g.*, §II.A; EX1002 ¶93. While these solutions were effective in treating myopia, they caused several side effects, such as photophobia, cycloplegia, and mydriasis, which resulted in poor compliance. *E.g.*, EX1012 ¶[0006]; EX1015, 1; EX1014, 3; EX1013, 2; EX1045, 2, 5; EX1002 ¶94.

Recognizing this problem, *Chia* studied the efficacy of lower concentration formulations and demonstrated that 0.01% atropine solutions were clinically effective to treat myopia, explaining that “atropine 0.01% has minimal side effects compared with atropine at 0.1% and 0.5%, and retains comparable efficacy in controlling myopia progression” compared to higher-concentration solutions. EX1003, 13. *Chia* expressly promoted the use of these lower-concentration solutions, noting that such solutions were not yet commercially available and that their findings “collectively suggest that a nightly dose of atropine at 0.01% seems to be a safe and effective regimen for slowing myopia progression in children, with minimal impact on visual function in children.” EX1003, 19–20; see also EX1013, 5.

Chia’s success with 0.01% atropine and suggestion that it “seems to be a safe and effective regimen for slowing myopia progression in children” (EX1003, 20)

provided a motivation to pursue a stable, ready-to-use formulation for that treatment. EX1002 ¶¶95–98. Stability of ophthalmic solutions “is always a primary consideration, both in the bottle and in the tissues,” and was particularly important to low-concentration atropine where “the loss of even small amounts of drug...can become significant.” EX1046, 16; EX1047, 1–2. Because using atropine for myopia requires long-term treatment, a POSA would have been motivated to increase stability and shelf life of these low-concentration formulations. *E.g.*, EX1048, 5; EX1046, 15 (“[P]harmaceutical manufacturer[s] strive[] for a shelf-life measured in years.”).

A POSA would have been further motivated towards a formulation that could maintain long-term stability when formulated at pHs closer to the pH 7.4 optimal for comfort, and thus, patient compliance and adherence. *E.g.*, EX1005, 52; EX1048, 4–5; EX1002 ¶¶99–103. As *Kondritzer* demonstrates, atropine was substantially stable at pH 3–5. EX1004, 6, 8 (Table III); EX1049, 1; EX1033, 1. This acidic pH, however, causes patient discomfort and irritation and leads to the same issue of low compliance that plagued the higher-concentration formulations. EX1050, 7; EX1015, 1; EX1012 ¶[0006]. Moreover, lower pH causes excess tearing that negatively impacts the bioavailability and clinical efficacy of individual doses. EX1046, 8; EX1051, 2; EX1047, 2 (“[T]ears are mainly responsible for the short residence time and low absorption of drugs applied topically to the eye.”).

Thus, a POSA would have been motivated to increase the long-term stability of *Chia*'s low-concentration atropine at pHs closer to the clinically desirable pH 7.4. EX1002 ¶¶99–103. As discussed below, *Siegel*'s use of D₂O with the structurally similar procaine was an obvious route to improving the stability of *Chia*'s low-concentration atropine for long-term use.

2. A POSA Would Have Been Motivated to Use D₂O to Increase Long-Term Stability of a Low-Concentration Atropine Formulation

Considering *Siegel*, a POSA would have recognized that deuterium oxide could reduce the degradation of atropine at pH levels more optimal for clinical efficacy and improve long-term shelf life. EX1002 ¶¶104–110. *Siegel* explicitly states that deuterium oxide “may prove of value, for example, in the extemporaneous preparation of ophthalmic solutions, where stability and sterility are important considerations.” EX1006, 4. *Siegel* further recognized an earlier study which found the efficacy of procaine in deuterium oxide was greater in D₂O by a factor of two and that the increased activity is “attributed to a greater stability (in vivo) of procaine base in deuterium oxide.” *Id.*, 4–5; *see also* EX1052, 4 (disclosing using D₂O to “stabilize and thus prolong the long term shelf-life”); EX1029, 20. Thus, a POSA would have understood from *Siegel* that D₂O could increase the efficacy and long term stability of ophthalmic solutions. EX1002 ¶¶58, 104–105.

A POSA would have also known that the SIE seen for procaine in D₂O was attributable to its mechanism of degradation, base-catalyzed hydrolysis, and that, in general, carboxylic acids degraded by base-catalyzed hydrolysis exhibited SIEs in D₂O. *See* EX1002 ¶¶50–54, 106–107; EX1006, 4; EX1025, 63; *infra*, §X.A. Likewise, it was understood that the effect of D₂O on the rate of reaction was predicted by the effect seen on structurally related compounds and “by analogy with known reaction mechanisms.” EX1025, 26; *see also id.*, 45–49; EX1002 ¶¶48–49.

Considering *Kondritzer*, a POSA would have recognized that procaine and atropine share several similarities. EX1002 ¶¶106–111. Atropine, like procaine, is a carboxylic ester, degrades via base catalysis, and its rate of degradation is driven by OH[–] concentration. EX1002 ¶¶107–108; EX1004, 6; EX1006, 4. Also like procaine, atropine is a weak base and its pK_a of 9.9 is similar to procaine’s pK_a of 8.8. EX1002 ¶109; EX1053, 41–42; EX1054, 2. Thus, a POSA would have understood that D₂O reduces the rate of base-catalyzed ester hydrolysis and would therefore be expected to increase the stability of atropine, which likewise degrades via base-catalyzed ester hydrolysis. EX1002 ¶¶106–111.

Moreover, as *Siegel* recognized, “since deuterium oxide resembles protium oxide (ordinary water) more closely than any other solvent” (EX1006, 4), the substitution of D₂O would not be expected to negatively influence the stability of atropine or otherwise detract from its clinical efficacy. EX1002 ¶112; EX1052, 4

(“[N]o new decomposition products...to be expected, besides those which are known from ordinary water....”); EX1023, 16. The simple substitution of D₂O for H₂O held the potential to improve the shelf-life and clinical efficacy without affecting any of the other beneficial properties. EX1002 ¶113; EX1029, 1, 6–8, 18–20; EX1030, 7–9; EX1023, 7–9. Thus, a POSA would have been motivated to make this substitution since it offered a desired improvement without an adverse effect on clinical efficacy. *Incyte Corp. v. Concert Pharms. Inc.*, IPR2017-01256, Paper 119, at 27 (PTAB Apr. 8, 2019) (finding motivation to modify known pharmaceutical with deuterium based on “the potential to improve the safety, tolerability, and efficacy of those compounds”); *Daiichi Sankyo Co. v. Matrix Labs., Ltd.*, 619 F.3d 1346, 1352 (Fed. Cir. 2010) (motivation based on expectation of “similar or improved properties compared with the old”).

Finally, between *Siegel*’s publication and the priority date of the ’447 patent, D₂O had become more widely available. *E.g.*, compare EX1029, 11 and EX1027, 3 (“Enough D₂O is now available for exploring its physical, chemical, and biological properties, and subsequent application in biological systems”), with EX1006, 4 (disclosing price of D₂O reasonable to “study” its effect on procaine); *see also* EX1002 ¶115; EX1023, 16. As shown below in Figure 2, the decade preceding the priority date of the ’447 patent saw an explosion in the use of deuterium to improve upon known pharmaceuticals. EX1002 ¶114; *see also* EX1056, 3; EX1031, 5. As

a 2011 article noted, “It is remarkable that these activities have their roots more than 40 years ago when in the 1960s first corresponding results were published.” EX1030, 14.




Figure 2. Left: EX1055, 68 (Fig. 10.4) Right: EX1032, 15 (Fig. 2)

Since *Siegel*'s publication, numerous researchers had recognized D₂O's potential to improve known pharmaceuticals. *E.g.*, EX1002 ¶¶60–63, 115–116; EX1029, 1, 6–8, 18–20; EX1030, 7–9, 13–14; EX1027, 1–2; EX1057, 6 (“D₂O itself has an effect in increasing the stability of the compositions of the invention.”). For example, *Teva* used D₂O to reduce hydrolysis of carboxylic acid derivatives in aqueous solution and explained that “stability...for long-term storage can be enhanced by replacing at least a major part of the ordinary water in such compositions by deuterium oxide.” EX1052, 2. A 2014 presentation titled “The use of deuterium oxide to stabilize pharmaceuticals against chemical degradation”

explicitly taught that “Deuterium oxide improve[s] stability of unstable drugs” was an “Expected Outcome” of D₂O modification. EX1029, 1, 20.

3. A POSA Would Have Had a Reasonable Expectation of Success in Substituting D₂O for H₂O in a Low-Concentration Atropine Formulation

A POSA would have had a “reasonable expectation of success in deriving *the claimed invention* in light of the teachings of the prior art.” *See Amgen, Inc. v. F. Hoffman-La Roche Ltd.*, 580 F.3d 1340, 1362 (Fed. Cir. 2009). Aside from the substitution of D₂O, the claims of the ’447 patent recite standard ophthalmic solutions of 0.001%–0.03% atropine proven effective against myopia in large scale clinical trials. *E.g.*, EX1003, 13, 15–20; EX1014, 1; EX1017, 1; EX1002 ¶¶25–36. D₂O did not present any unique formulation issues and had been incorporated into numerous ophthalmic therapeutics. *E.g.*, EX1002 ¶118; EX1006, 4–5; EX1058, Abstract (“A deuterated ocular solution is applied to an eye. The deuterated ocular solution includes deuterated water and one or more ocular drugs.”); EX1059, 8 (“The invention relates...to the use of deuterium oxide for the production of a drug for the prevention and/or treatment of virus-based diseases of the eye.”); EX1087, 1. Accordingly, there was a reasonable expectation of success in achieving the claimed invention. EX1002 ¶¶117–118.

There was also a reasonable expectation that the claimed formulations would have improved stability compared to solutions containing regular water. EX1002

¶119. *Siegel* taught that at pD levels close to those of the '447 claims, D₂O increased the stability of procaine by a factor of 2–3. EX1006, 5. Owing to the similarities in structure and degradation reactions between procaine and atropine, a POSA would have reasonably expected that a similar SIE would be seen for atropine as was seen for procaine. EX1002 ¶¶107–111; EX1025, 26, 32, 63. The expectation of success was bolstered by the art as a whole, which was replete with literature demonstrating that D₂O increased the stability of carboxylic acids subject to base-catalyzed ester hydrolysis. EX1002 ¶¶49–54, 119; EX1060, 4; EX1061, 4; EX1054, 2; EX1062, 3; EX1063, 4; EX1064, 4.

C. Claim-by-Claim Analysis

1. Claim 1

a. 1[a] “An ophthalmic composition, comprising...”

Should the preamble be construed as limiting, *Chia* renders it obvious. *Chia* disclosed administration of an atropine eye drop solution for the treatment of myopia. EX1003, 13, 19–20. Atropine is a known ophthalmic compound, (EX1003, 13), and atropine solutions such as those disclosed in *Chia* are a species of ophthalmic compositions. EX1002 ¶¶121–123. *Atlas Powder Co. v. IRECO, Inc.*, 190 F.3d 1342, 1346 (Fed. Cir. 1999) (“[A] single prior art species within the patent’s claimed genus reads on the generic claim...”).

b. 1[b] “one and no more than one ophthalmic agent”

Chia renders this limitation obvious. EX1002 ¶¶124–126. Atropine sulfate is the only ophthalmic agent in *Chia*’s atropine solutions. EX1003, 14; EX1002 ¶125. Moreover, the art showed that administering atropine as a monotherapy—*i.e.*, “comprising one and no more one ophthalmic agent” —was standard practice in the treatment of myopia. *E.g.*, EX1014, 1; EX1005, 52; EX1067, 9.

c. 1[c] “and deuterated water”

Siegel renders this limitation obvious. EX1002 ¶¶127–135. *Siegel* disclosed ophthalmic solutions comprising D₂O, taught that D₂O increased the long-term stability and clinical efficacy of procaine, and expressly motivated its use, stating that D₂O: “may prove of value, for example, in the extemporaneous preparation of ophthalmic solutions, where stability and sterility are important considerations.” EX1006, 4–5. Given the similarities of atropine and procaine discussed above, a POSA would have been motivated to apply the teachings of *Siegel* to the low-concentration formulations championed by *Chia*. EX1002 ¶128.

As *Siegel* demonstrated, D₂O offered the potential to improve the stability of low-concentration atropine solutions without negatively affecting their beneficial properties—*i.e.*, the efficacy in treating myopia established by *Chia*. EX1002 ¶¶133–134. As a POSA would have understood, this increased stability would have been particularly desirable for *Chia*’s atropine solutions, which required long-term

use, had to balance pH against stability for optimal clinical efficacy, and were of low concentration such that the loss of small amounts to degradation could negate efficacy. EX1002 ¶¶131–132.

First, long-term shelf life is unquestionably beneficial, as it allows the solutions to remain effective for longer periods than comparable H₂O formulations. EX1002 ¶130; EX1088, 4; EX1080, 7; EX1046, 15. This was particularly beneficial to atropine, which requires long term use to effectively treat myopia. *E.g.*, EX1002 ¶130; §§VIII.B.1–2. *Siegel*'s use of D₂O followed the art: “As [was] well known, deuterium oxide is itself both stable and effectively non-toxic....It is therefore an ideal solvent medium for [increasing long-term stability].” EX1052, 3.

Low-concentration atropine also had to be formulated at a pH that balanced long-term stability against clinical efficacy. EX1002 ¶131. While lower pH solutions were more stable, the increased acidity at these lower pHs undermined patient compliance and long-term efficacy; indeed “2- to 3-year stability often [was] achieved only by virtue of compromise.” EX1005, 54. Further, increased stability was especially beneficial to low-concentration atropine formulations, where “the loss of even small amounts of drug...can become significant.” EX1046, 16; EX1047, 1–2; EX1051, 2. D₂O offered the potential to improve upon the long-term stability of the low-concentration formulations, while increasing the pH levels to those more optimal for clinical efficacy. §§VIII.B.1–2.

The POSA's motivation was bolstered by the “utterly predictable” nature of deuterium modification (EX1023, 17)—the simple substitution of D₂O would have been expected to result in a product at least as effective as the H₂O formulation used successfully by *Chia*. EX1002 ¶¶133–134; EX1052, 4. Aside from being heavier, deuterium oxide is nearly identical to water in most other respects. EX1002 ¶¶55–57; EX1028 ¶[0011]; EX1023, 8–9; EX1022, 9; *see Conopco, Inc. v. The Proctor & Gamble Company*, IPR2013-00505, Paper 69, at 21 (PTAB Feb. 10, 2015) (“Where two known alternatives are interchangeable for a desired function, an express suggestion to substitute one for the other is not needed to render a substitution obvious.”) (citing *In re Fout*, 675 F.2d 297, 301 (CCPA 1982)).

Finally, motivation may be based on “common knowledge [or] the prior art as a whole.” *Pfizer, Inc. v. Apotex, Inc.*, 480 F.3d 1348, 1362 (Fed. Cir. 2007). While *Siegel* disclosed the benefits of D₂O with a close structural analog of atropine, the targeted effect of deuterium—*i.e.*, its ability to increase stability while leaving all other properties unchanged—was textbook science. *E.g.*, EX1002 ¶¶57–64; EX1023, 5–9. Because motivation may be based on an expectation of “similar or improved properties,” this alone provided the POSA sufficient motivation to modify *Chia*'s low-concentration atropine with D₂O. *Daiichi*, 619 F.3d at 1352; *see also Incyte*, IPR2017-01256, Paper 119 at 27.

d. 1[d] “at a pD of from about 4.2 to about 7.9”

Kondritzer and *Siegel* render this limitation obvious. EX1002 ¶¶136–143.

It was well known that pH is a result-effective variable for stability and patient comfort. *Id.* ¶¶138–139. *Kondritzer* taught that the rate of degradation is dependent on OH⁻ concentration, (*i.e.*, pH) (EX1004, 5–6, 8) and it was well understood that “comfort in the eye” is dependent on pH (EX1005, 52). Optimization of pH was routine in ophthalmic solutions where selection of the “proper pH...often represent[s] a compromise between stability of the drug and comfort in the eye.” EX1005, 52. *Kondritzer* explicitly supported such optimization, disclosing atropine’s stability is optimum at pH 3–5 (pD 3.4–5.4) (EX1004, 8), stability predictions between pH 2 and pH 7 (*id.*, 8), and referencing prior studies at pH 4–5 (pD 4.4–5.4) and pH 2.8–6 (pD 3.2–6.4) (*id.*, 6). EX1002 ¶140. As pH was a well-known result-effective variable, and these ranges overlap with and/or are encompassed by the pD 4.2–7.9 range of claim 1, the claimed range was obvious. *E.I. DuPont de Nemours & Co. v. Synvina C.V.*, 904 F.3d 996, 1010 (Fed. Cir. 2018) (“[D]iscovery of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.”) (quoting *In re Boesch*, 617 F.2d 272, 276 (CCPA 1980)).

Further, it would have been obvious to formulate the claimed atropine solution at pD 5.4–6.4 (pH 5–6) based on the teachings of *Kondritzer* and *Siegel*. EX1002

¶¶141–142. Such a composition falls squarely within and renders obvious the claimed range. *See Alcon Res., Ltd. v. Apotex Inc.*, 687 F.3d 1362, 1368 (Fed. Cir. 2012) (“[I]f prior art discloses a portion of the claimed range, the entire claim is invalid”); *Ormco Corp. v. Align Tech., Inc.*, 463 F.3d 1299, 1311 (Fed. Cir. 2006); *In re Peterson*, 315 F.3d 1325, 1329 (Fed. Cir. 2003).

To balance long term stability with clinical considerations, a POSA would have been motivated towards a pH between pD 5.4 (pH 5)—the high end of optimum stability according to *Kondritzer*—and pD 7.8 since “[i]deally, ophthalmic preparations should be formulated at a pH equivalent to the tear fluid value of 7.4 [i.e., pD of 7.8].” EX1005, 54. A POSA would have been motivated to get close to pD 7.8, but would have recognized that above pD 6.4 “hydrolysis became very rapid.” EX1004, 6. Thus, a POSA would have recognized that pD 5.4–6.4 was optimal. EX1002 ¶141.

The motivation and reasonable expectation of success for these higher pD levels was further bolstered by *Siegel*, which demonstrated that D₂O -atropine solutions would be expected to have increased stability compared to H₂O solutions. EX1006, 5; EX1002 ¶142. And the obviousness of pD 5.4–6.4 is underscored by it being bracketed by the pH ranges already shown to work for atropine in the treatment of myopia. EX1065, 2 (“The pH value of the product should be 4.0~6.0 [pD 4.4–

6.4].”); EX1066, 3 (pH 3.5–6 [pD 3.9–6.4]); EX1086; EX1067, 3 (pH 4–6 [pD 4.4–6.4]); EX1002 ¶143.

e. 1[e] “wherein the ophthalmic agent consists of atropine, atropine sulfate or a combination thereof”

Chia renders this limitation obvious. EX1002 ¶¶144–146. As discussed above, *Chia* disclosed the use of atropine solutions to treat myopia. EX1003, 13, 19–20. Moreover, the art showed that the “most widely studied pharmacological agent for the inhibition of myopia progression has been atropine” (EX1013, 2) and was replete with references teaching the use of atropine solutions to treat myopia. *E.g.*, §VIII.B.1; EX1002 ¶¶25–36, 146.

f. 1[f] “at a concentration of from about 0.001 wt % to about 0.03 wt %”

Chia renders this limitation obvious. EX1002 ¶¶147–151. *Chia* discloses that “[t]he lowest concentration of 0.01% atropine...is a viable concentration for reducing myopia progression” and that “the 0.01% formulation exhibited fewer adverse events” than 1%, 0.1%, and 0.5% atropine. EX1003, 19–20; *see also id.*, 13–14. Moreover, *Chia* provides express motivation, disclosing that 0.01% atropine was not yet commercially available and concluding that their “findings collectively suggest that a nightly dose of atropine at 0.01% seems to be a safe and effective regimen for slowing myopia progression in children, with minimal impact on visual function in children.” EX1003, 20; EX1002 ¶149. The efficacy of low

concentration atropine was well established in the art. *See, e.g.*, EX1018, 19:12–13; EX1014, 1; EX1002 ¶150.

2. Claim 2

Dependent claim 2 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition has a pD of one of: less than about 7.3, less than about 7.2, less than about 7.1, less than about 7, less than about 6.8, less than about 6.5, less than about 6.4, less than about 6.3, less than about 6.2, less than about 6.1, less than about 6, less than about 5.9, less than about 5.8, less than about 5.2, or less than about 4.8 after extended period of time under storage condition.” EX1001, claim 2. The combination of *Chia*, *Siegel*, and *Kondritzer* renders this additional feature obvious. EX1002 ¶¶152–158.

As discussed above, an “extended period of time” should be construed as at least one week. There was a reasonable expectation of success that the formulations of claim 1 at least at the obvious pD of 5.4–6.4 (§VIII.C.1.d) would meet the stability limitation of claim 2. *See Santarus, Inc. v. Par Pharms., Inc.*, 694 F.3d 1344, 1354 (Fed. Cir. 2012) (“an obvious formulation cannot become nonobvious” by claiming its properties); *In re Baxter Travenol Labs.*, 952 F.2d 388, 392 (Fed. Cir. 1991).

A prior study of atropine eye drops at pH 5 (pD 5.4) showed no statistically significant variation in pH over thirty days. EX1050, 5. Similarly, the art showed that over the course of one year, “[t]here were slight increases in pH [of an atropine

formulation], of 1.08, 0.77, and 0.41 at 35°C, 23°C, and 5°C, respectively.” EX1068, 3. A formulation with an initial pD of 5.4 would be expected to increase by, at most, 1.08 over the course of one year and would be well within the bounds set by claim 2—*e.g.*, “less than 7.3.” Over the course of a one-week period, this variation would be substantially less, even if measurable. EX1002 ¶¶155–156. And, as demonstrated by this example, if the Board construes an “extended period of time” as a period longer than at least one week, claim 2 would still be obvious. EX1002 ¶157.

3. Claim 3

Dependent claim 3 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic agent is present in the composition at a concentration of one of: from about 0.001 wt % to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt %, from about 0.001 wt % to about 0.01 wt %, from about 0.001 wt % to about 0.008 wt %, or from about 0.001 wt % to about 0.005 wt %.” EX1001, claim 3.⁹ *Chia* renders this additional feature obvious. EX1002 ¶¶159–162.

As explained above, *Chia* disclosed administration of 0.01% atropine compositions, a muscarinic agent at a concentration within the ranges recited by

⁹ A certificate of correction was filed for the ’447 patent changed “muscarinic antagonist” to “ophthalmic agent.” EX1098.

claim 3 (*e.g.*, “from about 0.001 wt % to about 0.025 wt %”). §VIII.C.1.f; EX1003, 13; *see KSR Int’l Co. v. Teleflex Inc.*, 550 U.S. 398, 419 (2007); *Atlas Powder*, 190 F.3d at 1346. Claim 3 imparts no patentability over claim 1 and would have been obvious for all the reasons discussed above. *See* §VIII.C.1.

4. Claims 6 and 7

Dependent claim 6 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition further comprises a preservative.” EX1001, claim 6. Dependent claim 7 recites: “The ophthalmic composition of claim 6, wherein the preservative is selected from benzalkonium chloride, cetrimonium, sodium perborate, stabilized oxychloro complex, SofZia, polyquaternium-1, chlorobutanol, edetate disodium, polyhexamethylene biguanide, or combinations thereof.” *Id.*, claim 7. *Chia* renders these additional features obvious. EX1002 ¶¶163–170.

Claim 7 recites a list of well-known, traditional preservatives used in atropine and other ophthalmic compositions. EX1002 ¶¶75–76, 166. *Chia* explicitly discloses that its “[t]rial medication consisted of the appropriate dose of atropine sulfate with 0.02% of 50% *benzalkonium chloride as a preservative*.” EX1003, 14. *Chia*’s disclosure reflected standard practice in the art. *E.g.*, EX1002 ¶¶167–168; EX1005, 55–56; EX1066, 3; EX1049, 2; *see also* EX1069, 8 (disclosing chlorobutanol to preserve eyedrops).

Because “[a] broader independent claim cannot be nonobvious where a dependent claim stemming from that independent claim is invalid for obviousness,” the obviousness of benzalkonium chloride as recited by claim 7 renders claim 6 obvious. *Comaper Corp. v. Antec, Inc.*, 596 F.3d 1343, 1350 (Fed. Cir. 2010); *Atlas Powder*, 190 F.3d at 1346.

5. Claim 12

Dependent claim 12 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition comprises one of: less than 5% of H₂O, less than 4% of H₂O, less than 3% of H₂O, less than 2% of H₂O, less than 1% of H₂O, less than 0.5% of H₂O, less than 0.1% of H₂O, or 0% of H₂O.” EX1001, claim 12. *Siegel* renders this additional feature obvious. EX1002 ¶¶171–177.

As explained above for claim 1, substituting deuterium oxide for regular water in 0.01% atropine solutions was obvious. §§VIII.C.1.c-f. *Siegel* disclosed that the D₂O solutions used to stabilize procaine consisted of 99% deuterium oxide. EX1006, 4. It would have been obvious to use the same levels of D₂O effective in increasing the stability of procaine to increase the stability of atropine. EX1006, 4–5; EX1002 ¶174.

Moreover, a POSA would have understood that higher levels of deuterium oxide—i.e., the 95% or more recited by claim 12—would lead to a greater solvent isotope effect, and, in turn, larger increases in stability compared to atropine

solutions with greater amounts of regular water. EX1022, 10–11 (reporting prior study finding “[t]he rate of hydrolysis [of acetylcholine bromide] was decreased 10.6% in 20% D₂O, 23% in 50% D₂O, and about 33% in 75% D₂O” compared to regular water); EX1070, 2; EX1064, 7 (Fig. 3). Conversely, lower concentrations of D₂O would simply mean that a greater proportion of the solution was regular water, and thus, would be less stable than the solutions containing >95% D₂O. EX1002 ¶¶175–176.

Consistent with this intuitive concept, the art as a whole demonstrated that use of high levels of deuterium oxide were standard practice in the art. *E.g.*, EX1052, 3 (“[P]harmaceutical compositions may contain, say, about 98% or 99% deuterium oxide, the balance being ordinary water.”); EX1063, 2 (“[T]he hydrogen content of the solvent...did not exceed 0.5 %”); EX1062, 2 (99.5% D₂O); EX1061, 1 (99.8% D₂O); EX1064, 2 (99.9% D₂O); EX1057, 10 (99.9% D₂O).

6. Claim 13

Dependent claim 13 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition is not formulated as an injectable formulation.” EX1001, claim 13. *Chia* renders this additional feature obvious. EX1002 ¶¶178–182.

Chia disclosed an atropine composition formulated for administration as “eye drops” (EX1003, 13–14) that a POSA would have understood was “not formulated

as an injectable solution.” EX1002 ¶180. To treat myopia, formulating atropine as topical solutions for instillation was standard practice (EX1002 ¶181); the art taught “instillation of eyedrops remains...one of the more accepted means of topical drug delivery.” EX1005, 49; *see also* EX1018, 18:2–4; EX1014, 1; EX1013, 1.

7. Claim 14

Claim 14 is identical to claim 1 except it recites an “ophthalmic solution” instead of an “ophthalmic composition.” *Chia* discloses an ophthalmic solution. EX1003, 13. Accordingly, claim 14 is obvious for all the reasons described for claim 1. §VIII.C.1; EX1002 ¶¶183–186.

8. Claim 15

With the exception of the language “ophthalmic solution,” claim 15 is identical to claim 2. *Chia* discloses an ophthalmic solution. EX1003, 13. Accordingly, claim 15 is obvious for all the reasons described for claim 2. §VIII.C.2; EX1002 ¶¶187–189.

9. Claim 16

With the exception of the language “ophthalmic solution,” claim 16 is identical to claim 12. *Chia* discloses an ophthalmic solution. EX1003, 13. Accordingly, claim 16 is obvious for all the reasons described for claim 12. §VIII.C.5; EX1002 ¶¶190–192.

10. Claim 17

Claim 17 recites “A method of arresting myopia progression, comprising administering to an eye of an individual in need thereof an effective amount of the ophthalmic compositions recited in claim 1. EX1001, claim 17. As discussed above, *Chia* and *Siegel* in view of *Kondritzer* rendered claim 1 obvious. §VIII.C.1. As *Chia* taught that its 0.01% atropine solutions were effective to treat myopia, a POSA would have found it obvious to use the solutions of claim 1 to treat myopia. EX1003, 13, 19–20; EX1002 ¶¶193–199.

Chia tested 0.01% atropine solutions in a clinical trial of 400 subjects. EX1003, 13. *Chia* taught that “[t]he lowest concentration of 0.01% atropine...is a viable concentration for reducing myopia progression” and that “the 0.01% formulation exhibited fewer adverse events” than 1%, 0.1%, and 0.5% atropine solutions. EX1003, 19–20.

There was also a reasonable expectation of success that the method of claim 17 would arrest myopia. EX1002 ¶¶196–199. Consistent with the art as a whole, *Chia* demonstrated that 0.01% atropine sulfate solutions significantly decreased the progression of myopia. EX1003, 13, 15–19; EX1014, 1, 3; EX1017, 1; EX1018, 19:12–13. D₂O substitution would not be expected to change the biological properties of the formulation compared to the solution formulated with regular

water, and thus would be expected to be at least as effective in treating myopia.

EX1002 ¶¶55–63, 198; §§VIII.B.2–3.

11. Claim 18

Dependent claim 18 recites: “The method of claim 17, wherein the ophthalmic composition is stored at between about 2° C. to about 10° C. prior to first use.”

EX1001, claim 18. *Kondritzer* renders this additional feature obvious. EX1002 ¶¶200–205.

Kondritzer specifically disclosed atropine solutions at 10° C and pH 3.97 (pD 4.37)—*i.e.*, solutions within the ranges of claim 18—and taught that the stability of atropine increases as storage temperature decreases at pHs within the ranges of claim 17 (*e.g.*, pH 4.5, 5). EX1004, 8; EX1002 ¶202. Stability was a key consideration for formulation, storage, and administration of atropine. §VIII.B.1; EX1002 ¶203. Thus, it would have been obvious to store the formulations recited by claim 1 at the low temperatures of claim 18 prior to first use for treating myopia, at least because those temperatures would enhance long-term stability. EX1002 ¶¶203–204; EX1050, 4; EX1068, 1 (disclosing storage of atropine formulations at 5° C); EX1047, 7; EX1057, 3; *see KSR*, 550 U.S. at 419; *Atlas Powder*, 190 F.3d at 1346.

12. Claim 19

Dependent claim 19 recites: “The method of claim 17, wherein the ophthalmic composition is stored at between about 16° C. to about 26° C. after first use.”

EX1001, claim 19. *Kondritzer* renders this additional feature obvious. EX1002 ¶¶206–210.

Kondritzer specifically disclosed atropine solutions at 20° C and pH 3.84 (pD 4.24)—*i.e.*, solutions within the ranges of claim 17—and taught that atropine is more stable at 20° C than at higher temperatures. EX1004, 8; EX1002 ¶208. Moreover, room temperature—*i.e.*, the temperature at which atropine would be stored under normal conditions—is 20°–22° C, encompassed by the range of claim 19. *See, e.g.*, EX1066, 5; EX1071, 1; EX1068, 1. It would have been obvious to store the formulations recited by claim 1 after first use for treating myopia at the same temperatures that H₂O -atropine formulations were stored. EX1002 ¶¶209–210; *see KSR*, 550 U.S. at 419; *Atlas Powder*, 190 F.3d at 1346.

IX. Ground 2: Claims 1–19 Would Have Been Obvious over *Chia*, *Siegel*, *Kondritzer*, and *Remington*

A. Summary of the Combination

As discussed above, claim 1 would have been obvious over *Chia*, *Siegel*, and *Kondritzer*. §§VIII.A–C. Claims 4–5 and 8–11 recite nothing more than standard components long used in atropine solutions for the treatment of myopia. EX1002 ¶¶66–74, 212–216. *Chia* discloses that it used 0.01% aqueous atropine solution with 0.01% BAK preservative, but it does not provide a full accounting of the components of the solutions. EX1003, 13. This is cured by *Remington*, which discloses standard ophthalmic formulations suitable for use in the atropine solutions. EX1005, 49–54.

Remington is a seminal text in the pharmaceutical sciences, which taught standard practices for ophthalmic formulations. *See, e.g.*, EX1002 ¶¶213–214; EX1005, 46, 49–54; EX1037 ¶[0073]; EX1072, 6, 24; EX1001, 42:7–11. A POSA would have been motivated to combine the well-known components disclosed by *Remington* with the atropine solutions of *Chia* at least because these components were known to provide safe and effective treatment. *E.g.*, EX1005, 51–52; EX1066, 3; EX1002 ¶215. Moreover, *Remington* expressly motivates the combination with atropine formulations such as *Chia*’s, disclosing a standard formulation, noting “[t]he following solutions are *suggested*” and explaining “[t]hese vehicles are suitable for salts of...atropine.” EX1005, 52; EX1002 ¶215.

As D₂O would not have been expected to change the biological properties of atropine or present any unique formulation issues (§§VIII.B.2–3), a POSA would have been motivated to use the same types of components that were established to work in atropine solutions containing regular water with a reasonable expectation of success. EX1002 ¶216.

B. Claim-by-Claim Analysis

1. Claims 1–3, 6–7, and 12–19

As explained above, the pD limitation recited by claims 1–3, 6–7, and 12–19 would have been obvious over *Chia*, *Siegel*, *Kondritzer* given the well-known fact that a pH of 7.4 (pD 7.8) was optimal for patient comfort. To the extent that the

Board finds an explicit disclosure of this teaching necessary, *Remington* disclosed it. EX1005, 54. EX1002 ¶218. Likewise, if the motivation to optimize pH is not sufficiently clear from *Kondritzer*, *Remington* explicitly disclosed “ophthalmic solutions are formulated to be...buffered for stability and comfort” (EX1005, 52), that “optimum pH [for stability] may be lower than preferable for product comfort, although this effect may be minimized by adjusting pH,” and provides a specific example of balancing pH for stability and comfort (EX1005, 54). EX1002 ¶219. Thus, for the same reasons discussed in Ground 1 and these additional reasons, claims 1–3, 6–7, and 12–19 would also have been obvious over *Chia*, *Siegel*, *Kondritzer*, and *Remington*. §§VIII.A–C; EX1002 ¶¶217–220.

2. Claims 4 and 5

Dependent claim 4 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition further comprises an osmolarity adjusting agent.” EX1001, claim 4. Dependent claim 5 recites: “The ophthalmic composition of claim 4, wherein the osmolarity adjusting agent is sodium chloride.” *Id.*, claim 5. *Remington* renders these additional features obvious. EX1002 ¶¶221–230.

Remington discloses an ophthalmic formulation suitable for atropine containing sodium chloride. EX1005, 52. *Remington* further taught “isotonicity always is desirable and particularly is important in intraocular solutions” and that “[a]n ophthalmic solution is considered isotonic when its tonicity is equal to that of

an 0.9% sodium chloride solution.” EX1005, 54. As Dr. Byrn explains, a tonicity adjusting agent is necessarily an osmolarity adjusting agent. EX1002 ¶226; EX1085, 16–19. The ’447 patent specifically discloses sodium chloride as a “tonicity adjusting agent” (EX1001, 3:18–28) and *Remington*’s disclosure reflected standard practice in the art. *E.g.*, EX1002 ¶¶227–229; EX1068, 2; EX1069, 2; EX1067, 2; EX1065, 1.

The obviousness of sodium chloride as recited by claim 5 renders claim 4 obvious. *Atlas Powder*, 190 F.3d at 1346; *Comaper*, 596 F.3d at 1350.

3. Claims 8 and 9

Dependent claim 8 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition further comprises a buffer agent.” EX1001, claim 8. Dependent claim 9 recites: “The ophthalmic composition of claim 8, wherein the buffer agent is selected from borates, borate-polyol complexes, phosphate buffering agents, citrate buffering agents, acetate buffering agents, carbonate buffering agents, organic buffering agents, amino acid buffering agents, or combinations thereof.” *Id.*, claim 9. *Remington* renders these additional features obvious. EX1002 ¶¶231–238.

Claim 9 recites a list of well-known, traditional types of buffers used in atropine and other ophthalmic compositions. *E.g.*, EX1002 ¶234; EX1005, 35–36, 41–43, 52. For example, *Remington* discloses a standard atropine formulation comprising sodium acid phosphate anhydrous and disodium phosphate anhydrous.

EX1005, 52. As Dr. Byrn explains, a POSA would have understood that sodium acid phosphate anhydrous and disodium phosphate anhydrous are both “phosphate buffering agents” as recited by claim 9. EX1002 ¶235; EX1073, 133; EX1074, 1; EX1075, 1.

The art shows that *Remington*’s disclosure was standard practice and further demonstrates that it would have been obvious to include buffers in the atropine compositions recited by claim 1. EX1002 ¶236; EX1069, 2, 20; EX1033, 4–5. For example, the FDA-approved atropine formulation contains dibasic sodium phosphate (disodium hydrogen phosphate) and monobasic sodium phosphate (sodium dihydrogen phosphate) as buffering agents. EX1066, 3.

The obviousness of phosphate buffers as recited by claim 9 renders claim 8 obvious. *Atlas Powder*, 190 F.3d at 1346; *Comaper*, 596 F.3d at 1350.

4. Claim 10

Dependent claim 10 recites: “The ophthalmic composition of claim 1, wherein the ophthalmic composition further comprises a pD adjusting agent.” EX1001, claim 10. *Remington* renders this additional feature obvious. EX1002 ¶¶239–245.

Remington taught that adjusting the pH of ophthalmic compositions was routine, explaining that “optimum *pH adjustment* usually requires compromise on the part of the formulator” (EX1005, 54) and instructs that the “solution *pH must be selected* for optimum drug stability.” (EX1005, 52). *Remington* also discloses a

standard formulation suitable for atropine which includes buffering agents. §X.B.3. A POSA would have understood that this disclosure is necessarily a “pD adjusting agent” (EX1002 ¶242)—indeed, *Remington* explicitly contemplates “adjusting pH with a buffer” (EX1005, 54).

Moreover, it was well known that pH could be adjusted independent of the buffer with acids and bases. EX1002 ¶¶68–72, 243; EX1076, 2–3, 6; EX1052, 5. Under “Pharmaceutical Necessities” *Remington* discloses standard components for such adjustment, including acetic acid and hydrochloric acid. EX1005, 36, 39. Specifically, *Remington* disclosed acetic acid is “used primarily as an acidifying agent” (EX1005, 36) and that hydrochloric acid is “[o]fficially classified as pharmaceutic aid that is used as an acidifying agent.” (EX1005, 39). A POSA would have understood that an “acidifying agent,” is a “pD adjusting agent.” EX1002 ¶243; EX1077, 10; see also EX1078, 9; EX1079 ¶[0174]; EX1028 ¶[0069].

5. Claim 11

Dependent claim 11 recites: “The ophthalmic composition of claim 10, wherein the pD adjusting agent comprises deuterated hydrochloric acid, deuterated sodium hydroxide, deuterated acetic acid, or deuterated citric acid.” EX1001, claim 11. *Remington* and *Siegel* render this additional feature obvious. EX1002 ¶¶246–254.

Claim 11 depends from claim 10 and further recites deuterated analogs of four standard pD adjusting agents. As explained (§IX.B.4), *Remington* specifically notes that acetic acid and hydrochloric acid were “acidifying”—i.e., pD adjusting—agents. EX1005, 36, 39; EX1002 ¶248. Indeed, these four agents were ubiquitous in the formulation of pharmaceuticals (EX1077, 29, 32, 39, 41) and had been used as pD adjusting agents in D₂O (EX1028 ¶[0069]), ophthalmic compositions (EX1078, 9; EX1050, 6), and the FDA approved atropine eyedrops (EX1066, 3). EX1002 ¶¶249–251. Moreover, both citric and acetic acid were known to be optimal within the claimed pD range (EX1080, 23; EX1081, 6) and the FDA-approved atropine formulation used “hydrochloric acid and/or sodium hydroxide” as “pH adjusting agents.” (EX1066, 3). EX1002 ¶¶250–251.

It would have been obvious to use deuterated analogs of the same common pD adjusting agents with atropine- D₂O compositions. EX1002 ¶¶252–253. *Siegel* discloses the use of deuterium oxide to increase the stability and clinical efficacy of ophthalmic solutions and specifically notes the use of “deuterium oxide buffers.” EX1006, 4. Moreover, *Siegel* references a prior study of procaine in D₂O by the same authors (EX1006, 5), which specifically used “*sodium hydroxide* for pH values 5.0 to 8.0” and explained that “[t]he deuterium oxide buffer systems were prepared from the same reagents except that all replaceable hydrogen was exchanged with

deuterium.” EX1082, 2. The art specifically contemplated using deuterated buffers in D₂O pharmaceutical products to correct for the pD-pH difference. EX1029, 18.

X. Alleged Unexpected Results

The alleged unexpected results are nothing more than the expected stabilization of the atropine solution due to D₂O, followed by basic arithmetic. EX1002 ¶¶255–257. Presented over thirty charts, “better stability,” “lower main degradant,” and “longer shelf life” are simply different ways of expressing the same expected effect of D₂O. Indeed, the Examiner recognized that “[t]he increased stability is the expected property of [atropine and D₂O] being used together.” EX1042, 3. To the extent they are relevant at all, the results are sourced from three highly specific formulations that are not remotely probative of the broad claims of the ’447 patent.

A. A Solvent Isotope Effect Was Not Unexpected

Patent owner failed to provide any explanation or prior art showing why increased stability in D₂O would have been “unexpected.” EX1094, 9–12; *see In re Baxter*, 952 F.2d at 392. As of the earliest possible effective filing date, an extensive body of literature showed that a slowed rate of reaction for carboxylic esters subject to base-catalyzed hydrolysis in D₂O would not be unexpected. EX1002 ¶¶258–266.

For example, Jencks 1961 reported that reaction rates were “decreased approximately two-fold” (EX1061, 2); Winter 1972 reported a SIE of 1.8–3.9 across

a series of five carboxylic esters (EX1060, 4 (Table 4); and Minor 1972 reported “solvent isotope effect of $k_{\text{H}_2\text{O}}/k_{\text{D}_2\text{O}} = 2.17$ ” for O-dichloroacetylsalicylic (EX1054, 1). EX1002 ¶¶261–265. These examples represent a fraction of carboxylic acids subject to base-catalyzed hydrolysis for which SIEs of similar magnitude had been reported. *See, e.g.*, EX1061, 6–7 (reporting “*the two- to threefold decrease in deuterium oxide solution of the rates of the reactions with water of these esters and of a number of other acyl compounds, including acetylimidazole, acetylimidazolium, acetic anhydride, acetyl phenyl phosphate and possibly acetylpyrazole and ethyl benzoate.*”); EX1064, 4 (Table I); EX1063, 4 (Table IV); EX1083, 3 (Tables I and II); EX1062, 3 (Table II) EX1060, 2 (Table 1); EX1002 ¶266. The data presented by Patent Owner for atropine would not have been unexpected to a POSA. EX1002 ¶¶259–260.

B. Data Presented During Prosecution

During prosecution, Patent Owner alleged that the D₂O formulations showed three advantages over their H₂O counterparts: (1) better stability; (2) lower main degradant; and (3) longer-shelf life. EX1094, 9–12. Obscured in myriad charts and figures (EX1001, p. 3–12, 70:59–82:28), this data amounts to nothing more than extrapolation from the same experiments, showing the same slowed reaction rate in D₂O, as reported by the numerous references above. EX1002 ¶267.

1. Better Stability Was Not Unexpected

During prosecution, Patent Owner compared the rate of degradation for the D₂O formulations to that of the corresponding H₂O formulations. EX1094, 9–10; EX1002 ¶¶268–269. Unsurprisingly, as shown below in Table 1, the SIE for atropine is directly in line with the litany of prior art references that studied the effect of D₂O on the base-catalyzed hydrolysis of carboxylic esters. EX1002 ¶¶270–273; §X.A.

Table 1

Pair-Wise Comparisons (’447 patent Table 24)	Solvent Isotope Effect		
	$k_{(H_2O)}/k_{(D_2O)}$		
	25°C	40°C	60°C
Formulations 3 & 7 ¹⁰ (pH 4.8/pD 5.2)	n.d.	0.50	0.69
Formulations 5 & 8 (pH 5.8/pD 6.2)	2.00	3.00	6.00
Formulations 10 & 9 (pH 6.4/pD 6.8)	2.33	2.25	2.04

¹⁰ At these lower pHs other degradation pathways are involved, and, in any event “The half life [of atropine]...between pH 3 and 5 is so great that its experimental determination is not practical.” EX1004, 8; EX1002 ¶273.

Formulations 11 & 9 (pH 6.4/pD 6.8)	2.33	2.56	2.60
Formulations 13 & 12 (pH 6.8/pD 7.2)	1.43	1.89	1.66

Moreover, as Dr. Byrn explains, the data in the '447 patent are based on single-run experiments, show large standard deviations, and appear to compare data generated with different experimental methods. EX1002 ¶¶274–276; *cf.* EX1084, 2, 5–10. Thus, while indicative of the expected qualitative increase in stability of the D₂O formulations, individual numerical variations are of little, if any, significance. EX1002 ¶277. For example, while the SIE of 6 for formulation 8 at 60°C would not have been unexpected (*e.g.*, EX1061, 4, EX1083, 3), the variation between this run and all the other data is likely due in part, if not entirely, to experimental error. EX1002 ¶277.

2. Lower Main Degradant Was Not Unexpected

“Lower main degradant” (EX1094, 11) is nothing more than a different way of measuring the same expected effect of D₂O discussed above (§X.B.1). EX1002 ¶278. In the “better stability” example, the rate of substrate (atropine) breakdown is measured, whereas this example measures the rate at which the resulting product (tropic acid) is formed. EX1001, 76:32–79:40; EX1002 ¶279. Unsurprisingly, as

shown in Table 2, the SIEs observed for the pair-wise comparisons largely match those of the “better stability” example. EX1002 ¶¶279–280.

Table 2

Pair-Wise Comparisons (’447 patent Table 25)	Solvent Isotope Effect		
	$k_{(H_2O)}/k_{(D_2O)}$		
	25°C	40°C	60°C
Formulations 3 & 7 (pH 4.8/pD 5.2)	0.62	1.13	1.48
Formulations 5 & 8 (pH 5.8/pD 6.2)	5.09	6.82	8.37
Formulations 10 & 9 (pH 6.4/pD 6.8)	2.51	2.14	2.23
Formulations 11 & 9 (pH 6.4/pD 6.8)	2.57	2.45	2.82
Formulations 13 & 12 (pH 6.8/pD 7.2)	1.82	1.96	1.78

As Dr. Byrn explains, the slight increase in the effect of D₂O seen in these measurements compared to those in “better stability” was also expected because the “lower main degradant” example measures the SIE more directly. EX1002 ¶280. This small difference is of no moment. As the ’447 patent acknowledges, “[t]his related substance is likely to be the first parameter to fail specification.” EX1001,

68:44–45. That is, as shown in the '447 patent's data, the shelf life of all of the formulations is governed by the rate of related substances, measured in the “better stability” example. EX1001, 81:56–82:28 (Table 30); EX1002 ¶¶280–281.

3. Longer Shelf Life Was Not Unexpected

Patent Owner then takes the data from these first two results and converts them into predicted shelf life based on the rate of degradation (formation of all related substances, *i.e.*, the total degradation of atropine measured in “better stability”) and product formation (tropic acid, *i.e.*, “lower main degradant”). EX1094, 12; EX1001, 80:60–82:28; EX1002 ¶282. This is yet another manner of expressing the same expected effect of D₂O. EX1002 ¶283.

It is textbook science that reducing the rate of reaction will increase the shelf life of the drug. EX1085, 36–37; EX1004, 6–8. Even accepting Patent Owner's calculations, the results are not unexpected. EX1002 ¶¶283–286. Indeed, these are not even results—they are merely predications done via simple arithmetic that produce superficially large distinctions (EX1094, 12–13), from the small, expected changes in stability caused by the SIE. EX1002 ¶¶283–286.

C. The Alleged Unexpected Results Are Neither Significant Nor Commensurate With the Scope of the Claims

Finally, to be probative of non-obviousness, differences must have been “unexpected *and significant*,” *Eli Lilly & Co. v. Zenith Goldline*, 471 F.3d 1369, 1378 (Fed. Cir. 2006)—the reported SIE is at best, an insignificant difference in

degree. EX1002 ¶¶287–289. *See Galderma Labs., L.P. v. Tolmar, Inc.*, 737 F.3d 731, 739 (Fed. Cir. 2013); *Accord Healthcare Inc. v. Daiichi Sankyo Co., Ltd.*, IPR2015-00864, Paper 104, at 29–30 (PTAB Sept. 12, 2016). Moreover, to the extent that they are relevant at all, Patent Owner’s data—which is sourced from formulations with specific pH levels and essentially free of regular water—are not probative of the ’447 patent’s broad claims; “objective evidence of non-obviousness must be commensurate in scope with the claims which the evidence is offered to support.” *In re Grasselli*, 713 F.2d 731, 743 (Fed. Cir. 1983); EX1002 ¶¶290–297.

All of the claims of the ’447 patent recite a broad range of pD 4.2–7.9 (pH 3.8–7.5). As pD is a logarithmic scale, this range spans a more than 5,000-fold difference in OH^- concentration. EX1002 ¶¶292–293. As explained (*e.g.*, §§II.B, VIII.C.2), the stability of atropine varies with OH^- concentration. EX1002 ¶293. The alleged unexpected results are limited to four specific pD levels that are not probative of the broad range claimed. EX1002 ¶294; EX1039, 10–13; *see E.I. DuPont*, 904 F.3d at 1012.

Further, with the exception of claims 12 and 16, none of the claims of the ’447 patent recite a specific level of deuterium oxide content. §§VIII.C, IX.B. As such, these claims would read on atropine formulations containing any amount of D_2O . EX1002 ¶295. It was well known that the SIE varies significantly with D_2O content. *E.g.*, EX1002 ¶296; EX1022, 10–11; EX1064, 7 (Fig. 3); EX1070, 2; *see also*

§VIII.C.5. All of the formulations presented for the alleged unexpected results were formulated in D₂O free of regular water. EX1001, 64:23–46. To the extent these results are relevant at all, they cannot be probative of claims that would read on a formulation comprising 1% or less D₂O. EX1002 ¶297.

XI. Non-Institution Under 35 U.S.C. § 325 Would Be Improper

Non-institution under § 325 would be improper based on weighing the factors in *Becton, Dickinson & Co. v. B. Braun Melsungen AG*, IPR2017-01586, Paper 8, at 17–18 (PTAB Dec. 15, 2017).

Regarding factors (a) and (b), the asserted combinations are materially different than and not cumulative of the prior art involved during examination of the challenged claims, *Teva*, *WoldeMussie*, *Wildsoet*. See §IV.B.2. During prosecution, the Examiner relied on *WoldeMussie* in combination with *Wildsoet* to teach an ophthalmic composition comprising 0.001%–0.3% atropine. *WoldeMussie* is directed to “treating glaucoma and/or ocular hypertension” with a range of muscarinic antagonists, none of which are atropine. *Wildsoet* is directed to a “hydrogel” “implanted into or around the eye,” (EX1037 ¶[0028]), discloses a laundry list of muscarinic antagonists (*id.* ¶[0030]), and does not disclose any muscarinic antagonist at concentrations of 0.001–0.3%. See also EX1093, 3. The combination in this IPR requires no such picking and choosing: *Chia* specifically

disclosed atropine eye drops at a concentration squarely within the claimed range were effective to arrest the progression of myopia. EX1003, 13, 19–20.

Similarly, *Teva*, disclosed D₂O in an injectable solution of benactyzine (EX1052, 4) for the treatment of poisoning. In contrast, *Siegel* disclosed D₂O to stabilize procaine—an ophthalmic agent—and explicitly taught that D₂O “may be of value” to the formulation of ophthalmic compositions. EX1006, 4–5. The Examiner did not consider any reference analogous to *Kondritzer*, which taught specific pHs within the ranges recited by the claims of the ’447 patent and demonstrated the applicability of the SIE to atropine. *See* §§VIII.A–C.

Regarding factors (c) and (d), there is little to no overlap because the Examiner did not use any of the ground references to reject any claim and did not make any arguments regarding them. EX1093, 2–5. *Siegel* was the only reference listed in a considered IDS, and it is not assumed that a reference was substantively evaluated when “the prior art was simply listed in an IDS during prosecution.” *Becton*, Paper 8 at 23; *see Netflix Inc. v. Hulu LLC*, IPR2020-00558, Paper 10 at 40 (PTAB Aug. 26, 2020) (granting institution and explaining “[b]ecause the combination...was not considered by the examiner, we find consideration of the references and arguments based thereon to be materially different than the examiner’s previous consideration....”).

Regarding factor (e), the Examiner erred in allowing the asserted claims to issue at least because “the Examiner was simply not aware” of the teachings of the most pertinent art and “[t]he Petition...presents different prior art than the Office was aware of.” *Oticon Med. AB v. Cochlear Ltd.*, IPR2019-00975, Paper 15 at 19–20 (PTAB Oct. 16, 2019) (precedential) (granting institution). Additionally, as discussed (§IV.B.2), despite acknowledging that “increased stability is the expected property of [atropine and D₂O] being used together” (EX1042, 3), the Examiner allowed the claims because of an amendment that excluded *Teva*’s disclosure of benactyzine and atropine in D₂O. That analysis did not consider that it was nonetheless obvious to improve low-concentration atropine with D₂O as a monotherapy for treating myopia. §IV.B.2; *see also* EX1002 ¶¶298–306.

Factor (f) is inapplicable because none of the asserted combinations were substantively considered by the Examiner. Weighing the remaining factors together, non-institution under § 325 would be improper.

Finally, there is no basis to exercise discretion under § 325(d) due to IPR petitions IPR2021-00439 through -00442, which included a petition challenging claims of the ’447 patent (IPR2021-00440). The Office never considered the proposed grounds in any of those proceedings which all settled prior to institution.

XII. Mandatory Notices Under 37 C.F.R. § 42.8

As set forth below and pursuant to 37 C.F.R. § 42.8, the following mandatory notices are provided as part of this Petition.

A. Real Parties-in-Interest

Eyenovia, Inc. is the real party in interest. Eyenovia, Inc. is not controlled by any other entity.

B. Related Matters

Sydnexis is the owner of the following U.S. applications and patents related to the '447 patent. U.S. Application No. 17/097,930 is pending and claims benefit of priority to U.S. Application No. 16/224,286, filed December 18, 2018, and issued as U.S. Patent No. 10,864,208, which is a continuation of U.S. Application No. 15/895,933, filed February 13, 2018, and issued as U.S. Patent No. 10,201,534, which is a continuation of U.S. Application No. 15/661,816, filed July 27, 2017, and issued as U.S. Patent No. 10,076,515, which is a continuation of U.S. Application No. 15/208,537, filed July 12, 2016, and issued as the '447 patent, which is a continuation of U.S. Application No. 14/726,139 (the "'139 application"), filed May 29, 2015, and issued as U.S. Patent No. 9,421,199 (the "'199 patent").

In addition, Sydnexis U.S. Patent No. 10,842,787 (the "'787 patent") issued from application number 15/568,381 (the "'381 application") which is a United States National Phase Application of International Application No.

PCT/US2016/029222, filed Apr. 25, 2016, which is a continuation in part of the '139 application that matured into the '199 patent. Sydnexis U.S. Patent No. 10,940,145 (the "'145 patent") issued from U.S. application No. 16/785,418 which is a continuation of U.S. application No. 16/677,538 (the "'538 application"). Sydnexis U.S. Patent No 10,888,557 (the "'557 patent") issued from U.S. application No. 16/785,413 is also a continuation of the '538 application. The '538 application, filed Nov. 7, 2019, is a continuation of the '381 application, which is a continuation in part of the '139 application, which issued as the '199 patent.

Nevakar, Inc. filed IPR2021-00439 challenging claims of the '199 patent on February 3, 2021, IPR2021-00440 challenging claims of the '447 patent on February 17, 2021, IPR2021-00441 challenging claims of the '515 patent on March 3, 2021, and IPR2021-00442 challenging claims of the '534 patent on March 18, 2021. All of those proceedings were terminated prior to any institution decisions or patent owner preliminary responses.

Petitioner filed IPR2022-00384 on December 29, 2021 challenging claims of the '787 patent. Petitioner also filed IPR2022-00414 and IPR2022-00415 on January 7, 2022, challenging claims of the '145 patent, and '557 patent respectively. All of those proceedings are currently pending. Petitioner is also concurrently filing petitions challenging claims of the '199 patent, the '515 patent, and the '534 patent.

Petitioner is not aware of any other judicial proceedings that may affect or be affected by a decision in this proceeding.

C. Lead and Back-Up Counsel, and Service Information

<p>Lead Counsel Peter J. Cuomo (Reg. No. 58,481) MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. One Financial Center Boston, MA 02111 Telephone: 617-348-1854 Facsimile: 617-542-2241 E-mail: PJCuomo@mintz.com</p>	<p>Back Up Counsel Thomas H. Wintner (<i>pro hac vice</i> to be filed) MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. One Financial Center Boston, MA 02111 Telephone: 617-348-1625 Facsimile: 617-542-2241 E-mail: TWintner@mintz.com</p> <p>Williams S. Dixon (Reg. No. 78,346) MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. One Financial Center Boston, MA 02111 Telephone: 617-348-4719 Facsimile: 617-542-2241 E-mail: WSDixon@mintz.com</p>
---	---

Petitioner consents to electronic service at the above email addresses.

XIII. Grounds for Standing

Eyenovia certifies the '447 patent is available for IPR and Eyenovia is not barred or estopped from requesting IPR challenging the patent claims on the grounds Identified herein.

XIV. Payment of Fees

Pursuant to 37 C.F.R. §§ 42.103 and 42.15(a), the requisite filing fee of \$41,500 (*inter partes* review request fee of \$19,000 and *inter partes* review post-institution fee of \$22,500) for a Petition for *Inter Partes* Review is submitted herewith. Claims 1–19 of the '447 patent are being reviewed as part of this Petition. The undersigned further authorizes payment from Deposit Account No. 50-0311 for any additional fees or refund that may be due in connection with the Petition.

XV. Conclusion

For the foregoing reasons, Petitioner respectfully requests that *inter partes* review be instituted and that claims 1–19 of the '447 patent be found unpatentable.

Dated: May 3, 2022

/Peter J. Cuomo/

Peter J. Cuomo (Reg. No. 58,481)

Thomas H. Wintner (*pro hac vice* to be filed)

Williams S. Dixon (Reg. No. 78,346)

MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, MA 02111

Telephone: 617-348-1854

Facsimile: 617-542-2241

Email: PJCuomo@mintz.com

TWintner@mintz.com

WSDixon@mintz.com

CERTIFICATE OF WORD COUNT

Pursuant to 37 C.F.R. § 42.24(d), Patent Owner hereby certifies, in reliance on the word count of the word-processing system (Microsoft Office Word 2010) used to prepare this petition, that the number of words in this paper is 13,620. This word count excludes the tables of contents, tables of authorities, mandatory notices under 37 C.F.R. § 42.8, certificate of word count, certificate of service, appendix of exhibits, and claim listing.

Dated: May 3, 2022

/Peter J. Cuomo/

Peter J. Cuomo (Reg. No. 58,481)

CERTIFICATE OF SERVICE

I certify that copies of the foregoing Petition for *Inter Partes* Review, all referenced exhibits, and the Petitioner's Power of Attorney were served on the Patent Owner at the correspondence address of record for the '447 patent by sending a copy by Priority Mail Express to:

WILSON SONSINI GOODRICH &
ROSATI
650 Page Mill Road
Palo Alto, CA 94304-1050

Dated: May 3, 2022

/Peter J. Cuomo/

Peter J. Cuomo (Reg. No. 58,481)